AUGUST 29-SEPTEMBER 2, 2016 Cover MARRIOTT LONG WHARF CAMBRIDGE HEALTHTECH INSTITUTE’S 4TH ANNUAL BOSTON, MA

Conference- at-a-Glance IO Immuno-Oncology SUMMIT Collaborating to Develop the Next Generation of Targeted Immunotherapy Keynotes

REGISTER BY JULY 29 AND SAVE UP TO $200! Faculty

Short Courses

Sponsor & Exhibit Opportunities Conference Programs Plenary Keynote Speakers Training Seminar Immunomodulatory Combination Adoptive T Cell Antibodies Immunotherapy Therapy Agenda Oncolytic Virus Personalized Biomarkers Immunotherapy Immunotherapy for Immuno-Oncology Edward Michael Morganna Hotel & Travel Fritsch Rosenzweig Freeman Information Ph.D., Chief Ph.D., Executive D.O., Associate Director, Training Seminar: Preclinical & Clinical Trials Technology Director, Biology- Melanoma & Cutaneous Ts Immunology for Drug Translational for Cancer Officer, Neon Discovery, IMR Early Oncology Program, Discovery Scientists Immuno-Oncology Immunotherapy Therapeutics, Inc Discovery, Merck Re- The Angeles Clinic and Registration search Laboratories Research Institute Information CORPORATE SPONSORS CORPORATE SUPPORT SPONSORS

Click Here to Register Online! Immuno-Oncology Summit.com

250 First Avenue Needham, MA 02494 www.healthtech.com Cover IO Immuno-Oncology SUMMIT Conference- at-a-Glance MEET THOUGHT LEADERS IN CANCER IMMUNOTHERAPY AT THE PREMIER ANNUAL IO EVENT As our understanding of tumor immunology combinations through clinical development and Who Will Attend? Keynotes has advanced, immuno-oncology has made into the market. This weeklong, nine-meeting set Scientific leaders, C-level executives, professors, unprecedented progress in improving the will include topics ranging from early discovery site directors and researchers from pharma, outcomes for cancer patients. Still, with the field through clinical development as well as emerging biotech, academia, and government working in Faculty in its infancy, the full curative potential of IO has areas such as oncolytic virus immunotherapy. the areas of immuno-oncology, immunotherapy, yet to be realized. CHI’s 4th Annual Immuno- Overall, this event will provide a focused look antibody and protein engineering, biomarker Oncology Summit has been designed to support at how researchers are applying new science discovery, immunology, cell and gene therapy, a coordinated effort by industry players to bring and technology in the development of the next and preclinical and clinical development. Short Courses commercial immunotherapies and immunotherapy generation of effective and safe immunotherapies.

Sponsor & Exhibit CONFERENCE AT-A-GLANCE Opportunities MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY

Training Seminar

Agenda Immunomodulatory Combination Adoptive T Cell Hotel & Travel Antibodies Immunotherapy Therapy Information

Registration Information

Oncolytic Virus Personalized Biomarkers for Click Here to Immunotherapy Immunotherapy Immuno-Oncology Register Online! Immuno-Oncology Summit.com

Training Seminar: Preclinical & Clinical Trials Immunology for Drug Translational for Cancer Discovery Scientists Immuno-Oncology Immunotherapy 250 First Avenue Needham, MA 02494 www.healthtech.com Cover Plenary Keynotes TUESDAY | AUGUST 30

Conference- at-a-Glance

Keynotes 4:00 Personalized, Neoantigen- 4:30 Emerging Innate Immune Targets for 5:00 Reading Tea Leaves: The Dilemma of Based Immunotherapy Enhancing Adaptive Anti-Tumor Responses Prediction and Prognosis in Immunotherapy Faculty Edward Fritsch, Ph.D., Chief Technology Michael Rosenzweig, Ph.D., Executive Morganna Freeman, D.O., Associate Director, Officer, Neon Therapeutics, Inc. Director, Biology-Discovery, IMR Early Melanoma & Cutaneous Oncology Program, Multiple lines of evidence have demonstrated the Discovery, Merck Research Laboratories The Angeles Clinic and Research Institute Short Courses critical role that Neoantigens have in the im- Novel cancer immunotherapies targeting T cell With the rapid expansion of immunotherapeutics mune response to cancer and the availability of checkpoint proteins have emerged as powerful tools in oncology, scientifically significant advances next-generation sequencing to identify personal, to induce profound, durable regression and remission have been made with both the depth and duration neoantigen-creating mutations has opened the of many types of cancer. Despite these advances, mul- of antitumor responses. However, not all patients Sponsor & Exhibit door to directly enhance the power and breadth of tiple studies have demonstrated that not all patients benefit, or quickly relapse, thus much scientific Opportunities host immunity to overcome this deadly disease. respond to these therapies, and the ability to predict inquiry has been devoted to appropriate patient se- which patients may respond is limited. Harnessing the lection and how such obstacles might be overcome. innate immune system to augment the adaptive anti-tu- While more is known about potential biomarkers, mor response represents an attractive target for ther- accurate prognostication persists as a knowledge Training Seminar apy, which has the potential to enhance both the per- gap, and efforts to bridge it will be discussed here. centage and rate of response to checkpoint blockade.

Agenda Jakob Dupont, M.D., Senior David M. Kranz, Track Keynotes Vice President & CMO, Ph.D., Phillip A. Sharp Hotel & Travel OncoMed Pharmaceuticals Professor of Biochemistry, University of Illinois Information

Prasad S. Adusumuilli, Kenneth Emancipator, Laszlo Radvanyi, Ph.D., M.D., FACS, Deputy Chief of M.D., Executive Medical Senior Vice President and Head, Registration Translational & Clinical Research, Director, Companion ImmunoOncology Translational Information Thoracic Surgery, Memorial Diagnostics, Merck & Co. Innovation Platform (TIP) EMD Serono Sloan-Kettering Cancer Center

Roy D. Baynes, M.D., Ronald Herbst, Ph.D., Vice Zhen Su, M.D., MBA, Senior Click Here to Ph.D., Senior Vice President President, R&D; Head, Oncology Vice President, Global Register Online! and Head, Global Clinical Research, MedImmune Head of Medical Affairs Development, Merck Oncology, EMD Serono Immuno-Oncology Research Laboratories Summit.com Edward Cha, M.D., Ph.D., Robert Iannone, M.D., Senior James E. Wooldridge, Associate Medical Director, Vice President & Head, Immuno- M.D., CSO, Immuno-Oncology Cancer Immunotherapy Oncology, Global Medicines Clinical Development, Franchise, Genentech Development, AstraZeneca Eli Lilly and Company

Robert Coffin, Ph.D., Ella Ioffe, Ph.D., Associate CEO, Replimmune Director, Immune-Oncology, 250 First Avenue Regeneron Pharmaceuticals Needham, MA 02494 www.healthtech.com Cover Join the conversation! Conference- at-a-Glance IOSUMMIT

Keynotes

Faculty

Short Courses

Sponsor & Exhibit Opportunities

Training Seminar

Agenda Distinguished Faculty Hotel & Travel Information

Adam J. Adler Roy D. Baynes Chris Boshoff Manel Cascallo Yeong “Christopher” Choi Anthony Davies Boris Engels Ph.D., Professor, M.D., Ph.D., Senior Vice M.D., Ph.D., Vice President Ph.D., Co-Founder, Ph.D., Director, TCPF Ph.D., COO, 4D Molecular Ph.D., Investigator, Immunology, University President and Head, Global and Head, Early, Develop- President and CEO, and Assistant Professor Therapeutics Exploratory Immuno-On- Registration of Connecticut Clinical Development, Mer- ment, Translational and VCN Biosciences of Oncology, Center for John Desjarlais cology, Novartis Institutes ck Research Laboratories Immuno-Oncology, Pfizer Immunotherapy, Roswell Information Prasad S. Adusumilli Saso Cemerski Ph.D., CSO, Xencor for Biomedical Research M.D., FACS, Deputy Chief of Stephen Beers Adrian Bot Ph.D., Associate Park Cancer Institute Luis Alberto Diaz Andrew M. Evens Translational & Clinical, Re- Ph.D., Associate Professor, M.D., Ph.D., Vice President, Principal Scientist, Merck Robert Coffin M.D., Associate Professor, D.O., Professor and Chief, search, Thoracic Surgery, Cancer Immunology and Translational Sciences, Research Laboratories Ph.D., CEO, Replimmune Oncology, Johns Hopkins Hematology/Oncology, Memorial Sloan-Kettering Immunotherapy, University R&D, Kite Pharma Inc. Edward Cha Joe Conner Sidney Kimmel Comprehen- Tufts University School Cancer Center of Southampton Click Here to Caroline Breitbach M.D., Ph.D., Associate Ph.D., CSO, Virttu Biologics sive Cancer Center of Medicine; Director, Omar Ali John Bell Ph.D., Vice President, Medical Director, Tufts Cancer Center Register Online! Michael A. Curran Gianpietro Dotti Ph.D., Staff Scientist, Wyss Ph.D., Senior Scientist, Translational Development, Cancer Immunotherapy Ph.D., Assistant Professor, M.D., Professor, Microbi- Christopher R. Heery Institute for Biologically Centre for Innovative Turnstone Biologics Franchise, Genentech Immuno-Oncology Immunology; Scientific Di- ology and Immunology, M.D., Director, Clinical Inspired Engineering, Cancer Research, Ottawa Summit.com Joshua Brody Brian Champion rector, ORBIT Platform MD University of North Carolina Trials Group, Laboratory of Harvard University Hospital Research Institute, M.D., Director, Lymphoma Ph.D., Senior Vice Anderson Cancer Center Tumor Immunology, Center Professor, Departments of Jakob Dupont Robert Anders Immunotherapy Program, President, R&D, PsiOxus for Cancer Research Medicine and Biochemistry, Adil Daud M.D., Senior Vice M.D., Ph.D., Associate Icahn School of Medicine Therapeutics Ltd Christian S. Hinrichs Microbiology & Immunol- M.D., Professor, Hematolo- President & CMO, OncoMed Professor, Pathology, at Mount Sinai Zhao Chen gy/Oncology, University of Pharmaceuticals MD, Investigator, Johns Hopkins University ogy, University of Ottawa Tullia Bruno Ph.D., Investigator III, California, San Francisco; Experimental Transplan- Kevin Bonham Kenneth Emancipator Philip M. Arlen Ph.D., Research Assistant Exploratory Immuno-On- Director, Melanoma Clinical tation and Immunology Ph.D., Curriculum Fellow, M.D., Executive Medical M.D., President & CEO, Professor, Immunology, cology, Novartis Institutes Research, UCSF Helen Branch, Lasker Clinical Microbiology and Immu- Director, Companion Precision Biologics, Inc. University of Pittsburgh for BioMedical Research Diller Family Comprehen- Research Scholar, NIH nobiology Department, Diagnostics, Merck & Co. sive Cancer Center Mark J. Federspiel Harvard Medical School Ph.D., Professor and Direc- tor, Viral Vector Production 250 First Avenue Laboratory, Mayo Clinic Needham, MA 02494 www.healthtech.com Continued on next page... Cover Continued from previous page...

Patrick Forde Robert Iannone Howard L. Kaufman Jennifer Mataraza Laszlo Radvanyi Craig L. Slingluff Alena Gros Vidal Conference- M.D., Assistant Professor, M.D., Senior Vice President M.D., FACS, Associate Ph.D., Senior Investigator, Ph.D., Senior Vice Jr., M.D., Joseph Helms Ph.D., Research Fellow, at-a-Glance Oncology, Sidney & Head, Immuno-Oncol- Director, Clinical Sciences, Immune Oncology, President; Head of Farrow Professor of Surgery Branch, National Kimmel Comprehensive ogy, Global Medicines Rutgers Cancer Institute Novartis Institutes for Immuno-Oncology Surgery; Vice-Chair for Cancer Institute Cancer Center, Johns Development, AstraZeneca of New Jersey; Professor BioMedical Research Translational Innovation Research; Director, Human Antti Vuolanto Hopkins University and Chief, Division of Platform (TIP), EMD Serono Immune Therapy Center, Ella Ioffe Patricia McCoon Ph.D., Executive Vice Surgical Oncology, Rutgers University of Virginia Morganna Freeman Ph.D., Associate Director, Ph.D., Principal Scientist, Paul Rennert President, Targovax Robert Wood Johnson Keynotes D.O., Associate Director, Immune-Oncology, Regen- Oncology IMED Translation- Ph.D., President & CSO, School of Medicine Medical School Jeffrey Wallin Melanoma & Cutaneous eron Pharmaceuticals al Science, AstraZeneca Aleta Biotherapeutics Inc. Susan R. Slovin Ph.D., Group Leader, Early Oncology Program, The Llew Keltner Pharmaceuticals M.D., Ph.D., Medical Pushpa Jayaraman Aaron Ring Stage Oncology Biomarker Angeles Clinic and M.D., Ph.D., CEO, EPISTAT Oncologist, Genitourinary Ph.D., Investigator II, Miriam Merad M.D., Ph.D., Assistant Development, Genentech Research Institute Exploratory Immuno-On- Arthur M. Krieg M.D., Ph.D., Chair, Professor, Immunobiology, Oncology Service, Faculty Steffen Walter Bruce Freimark cology, Novartis Institutes M.D. CEO, Checkmate Cancer Immunology, Yale University School Memorial Sloan Kettering Ph.D., CSO, Immatics Ph.D., Research Director, for BioMedical Research Pharmaceuticals Oncological Sciences, of Medicine Cancer Center Biotechnologies GmbH Preclinical Oncology, Tisch Cancer Institute, Suchit Jhunjhunwala David Kirn Scott Rodig Elena Spanjaard Peregrine Pharmaceuticals Mount Sinai Hospital Chan Whiting Ph.D., Scientist, M.D., CEO & Co-Founder, M.D., Ph.D., Associate Ph.D., Director, Worldwide Ph.D., Director, Immune Short Courses Jennifer Gansert Bioinformatics, Genentech 4D Molecular Therapeutics; Todd Metzger Professor, Pathology, Research & Development, Monitoring/Biomarker De- Ph.D., Executive Director, Regulatory Affairs, Pfizer Frank R. Jones Adjunct Professor, Ph.D., Senior Scientist, Harvard Medical School; velopment, Aduro Biotech Global Development Ph.D., Chairman & CEO, Bioengineering, University Cancer Immunology, Pfizer Associate Pathologist, David M. Spencer Lead, Amgen, Inc. of California, Berkeley Pathology, Brigham & Ph.D., CSO, Bellicum Jon Wigginton Etubics Corporation Janter Meulen M.D., CMO & Senior Sanja Gauthier Women’s Hospital Pharmaceuticals Sponsor & Exhibit Jennifer C. Jones Keith L. Knutson M.D., Dr.habil., DTM&H, Vice President, Clinical M.D., Senior M.D., Ph.D., Assistant Ph.D., Professor, CSO, Immune Design Arjan Roozen Pramod K. Srivastava Development, MacroGenics Medical Director, Immunology, Mayo Clinic Opportunities Clinical Investigator, Mo- Richard A. Morgan Vice President, Ph.D., M.D., Professor, Medical Safety Evaluation, Andy Williams lecular Immunogenetics & David M. Kranz Vice President, Immuno- GMP Solutions & Immunology and Medicine, Pharmacovigilance and Ph.D., Companion Vaccine Research Section, Ph.D., Phillip A. Sharp therapy, bluebird bio Manufacturing, Cellectis Director, Carole and Ray Patient Safety, AbbVie Diagnostics Group Vaccine Branch, National Professor of Biochemistry, Neag Comprehensive Spyro Mousses Michael Rosenzweig Leader, Cancer Immune Tariq Ghayur Cancer Institute, National University of Illinois Cancer Center, University Ph.D., President, Systems Ph.D., Executive Director, Therapies, Genentech Training Seminar Ph.D., Distinguished Institutes of Health of Connecticut School Arthur M. Krieg Imagination Inc. Biology-Discovery, IMR Research Fellow, AbbVie of Medicine Daniel Williams Karin Jooss M.D. CEO, Checkmate Early, Discovery, Merck Bioresearch Center Matthew Mulvey Head, UK Research Ph.D., CSO, Gritstone Pharmaceuticals Research Laboratories Zhen Su Ph.D., CEO, BeneVir Operations, Adaptimmune Oliver Ghobrial Oncology M.D., MBA, Senior Vice Kyle Landgraf Stephen J. Russell Ph.D., Principal Kuldeep Neote President, Global Head K. Dane Wittrup Agenda Pawel Kalinski Ph.D., Senior Scientist, M.D, Ph.D., Professor, Scientist, Translational Ph.D., Senior Director, of Medical Affairs Ph.D., Carbon P. M.D., Ph.D., Professor, Discovery Research, Mayo Clinic Informatics, Sanofi New Ventures, J&J Oncology, EMD Serono Dubbs Professor, Surgery, Immunology, and AvidBiotics Innovation Center Boston Catherine Sabatos-Peyton Chemical Engineering and Geoffrey T. Gibney Bioengineering, University Brad Thompson Jane Lebkowski Ph.D., Senior Investigator, Biological Engineering, M.D., Medical Oncologist, of Pittsburgh School of Cokey Nguyen Ph.D., CEO, Oncolytics Ph.D., President & CSO, Re- Novartis Institutes for Massachusetts Institute Hotel & Travel Georgetown-Lom- Medicine, University of Ph.D., Vice President, Biotech search and Development, BioMedical Research of Technology bardi Comprehensive Pittsburgh Cancer Institute R&D, Enumeral Information Asterias Biotherapeutics Christian Schmees Stephen Thorne Cancer Center James E. Wooldridge Cris Kamperschroer Fares Nigim Ph.D., Professor and Michael Lim Ph.D., Head of Tumor M.D., CSO, Immuno-Oncol- Sacha Gnjatic Ph.D., Associate M.D., Massachusetts Scientific Advisor, Inventor, M.D., Associate Professor, Biology, Molecular Biology ogy Clinical Development, Ph.D., Associate Professor, Research Fellow, Drug General Hospital Western Oncolytics Neurosurgery, Oncology Department, NMI Natural Eli Lilly and Company Tisch Cancer Institute, Safety R&D, Pfizer and Radiation Oncology, Patrick Alexander Ott and Medical Sciences Wolfgang Uckert Registration Hematology/Oncology, John Wrangle Vassiliki Karantza Johns Hopkins University M.D., Ph.D., Assistant Institute at the University Associate Professor, Immunology, Icahn School M.D., Assistant Professor, Information M.D., Ph.D., School of Medicine Professor, Medicine, Da- of Tübingen Department of Cell of Medicine at Mount Sinai Medicine, Hematology/On- Director, Clinical na-Farber Cancer Institute Biology and Gene Therapy, Douglas Linn Taylor Schreiber cology, Medical University Edward Fritsch Research Oncology, Merck Humboldt University Berlin Ph.D., Senior Scientist, In Michael J. Overman M.D., Ph.D., CSO, Heat of South Carolina Ph.D., Chief Tech- Research Laboratories Vivo Pharmacology, Merck M.D., Associate Professor, Biologics, Inc. Marit van Buuren nology Officer, Neon Jianda Yuan Noriyuki Kasahara Gastrointestinal Medical Jonathan Gilbert Ph.D., Scientist, Immunol- Therapeutics, Inc. Konstantin M. Linnik M.D., Ph.D., Director, M.D., Ph.D., Professor, De- Oncology, University ogy, Neon Therapeutics Click Here to Ph.D., Partner, Intellec- Director, Strategic Translational Immu- Jeffrey Hanke partments of Cell Biology of Texas MD Anderson tual Property, Nutter, Scientific Partnerships, Andrea van Elsas no-Oncology Research, Register Online! Ph.D., CSO, Tesaro and Pathology, Co-Leader, Cancer Center McClennen & Fish, LLP SQZ Biotech Ph.D., CSO, Aduro Biotech Merck Research Labs Immuno-Oncology Ronald Herbst Viral Oncology Program, Joseph Pearlberg Europe, The Netherlands Jason J. Luke Michail Sitkovsky Jonathan Zalevsky Ph.D., Vice President, University of Miami M.D., Ph.D., Senior Summit.com M.D., FACP, Assistant Ph.D., Professor, Janaki Veeraraghavan Ph.D., Vice President, R&D; Head, Oncology David Kaufman Medical Director, Infinity Professor, Medicine, Eleanor W. Black Chair, Ph.D., Biologist, Office Biology & Preclinical Research, MedImmune Ph.D., Executive Director, Pharmaceuticals Melanoma and Devel- and Director, New of In Vitro Diagnostics Development, Nektar Clinical Oncology, Merck Alex Yee-Chen Huang opmental Therapeutics Rodney Prell England Inflammation and and Radiological Health, Therapeutics Research Laboratories Ph.D., DABT, Principal Sci- Tissue Protection Institute, Center for Devices and M.D., Ph.D., Associate Clinics, University of Xingxing Zang entist/Toxicologist, Safety Northeastern University Radiological Health, FDA Professor, Pediatrics, Chicago Medical Center Ph.D., Associate Pathology & Biomedical Assessment, Genentech Ravi Madan Luis M. Vence Professor, Microbiology Engineering, Case M.D., Clinical Director, Maire Quigley Ph.D., Scientific Manager, and Immunology & Western Reserve University Genitourinary Malignan- Ph.D., Research Immunology, MD Anderson Medicine, Albert Einstein School of Medicine cies, Branch, National Investigator, Cell Process Cancer Center College of Medicine Cancer Institute, National Development, Cell & Gene 250 First Avenue Institutes of Health Therapies, Novartis Needham, MA 02494 www.healthtech.com Cover Short Courses MEDIA PARTNERS Conference- at-a-Glance Tuesday & Thursday Dinner Short Courses

TUESDAY, AUGUST 30 space to share insights and experiences on how Keynotes to advance this new field into clinical practice.

6:30-9:00 pm SC1: Targeting 6:30-9:00 pm SC2: Bispecific Antibody Faculty the Cancer Mutanome Development for Immunotherapy Laszlo Radvanyi, Ph.D., Senior Vice President; Sanja Gauthier, M.D., Senior Medical Head of Immuno-Oncology Translational Director, Medical Safety Evaluation, Innovation Platform (TIP), EMD Serono Pharmacovigilance and Patient Safety, AbbVie Luis M. Vence, Ph.D., Scientific Manager, Short Courses Cris Kamperschroer, Ph.D., Associate Immunology, MD Anderson Cancer Center Research Fellow, Drug Safety R&D, Pfizer Alena Gros Vidal, Ph.D., Research Fellow, Bispecific molecules designed to recruit T Surgery Branch, National Cancer Institute Sponsor & Exhibit cells and induce them to kill tumor cells are Opportunities Suchit Jhunjhunwala, Ph.D., Scientist, showing promise as cancer immunothera- Bioinformatics, Genentech pies. There are challenges to developing these Emerging sequencing and bioinformatics molecules, including safety concerns related technologies are now giving researchers new to the intended pharmacology of T cell activa- Training Seminar perspectives on the mutations in patient specific tion. This presentation will cover the nonclini- antigens, now collectively known as the cancer cal development of a specific T cell targeting mutanome. Our dinner short course offers bispecific molecule, its key safety concerns, academic and industry perspectives on the and approaches to mitigate the concerns. Agenda analytical and computational methods used to This short course will address: identify neo-epitopes within a mutanome that • Nonclinical development of a T cell are candidates for therapeutic intervention – and targeting bispecific molecule the potential applications of this knowledge in • Benefit/risk of bifunctional antibodies Hotel & Travel patient diagnostics and immunotherapy. An open in oncology clinical development Information discussion format will allow those working in this

Registration Information

Click Here to Register Online! Immuno-Oncology Summit.com

250 First Avenue Needham, MA 02494 www.healthtech.com Cover Sponsorship, Exhibit, & Lead Generation Opportunities Conference- at-a-Glance CHI offers comprehensive spon- workshop. Package includes exhibit delegates. Speak face-to-face with antee a minimum of 100 leads per sorship packages which include space, on-site branding, and access to prospective clients and showcase your program! Opportunities include: cooperative marketing efforts by CHI. latest product, service, or solution. • Whitepapers presentation opportunities, exhibit For the luncheon option, lunches are • Web Symposia Additional branding and Keynotes space, branding and networking delivered to attendees who are already • Custom Market Research Surveys promotional opportunities with specific prospects. Sponsor- seated in the main session room. • Podcasts are available, including: ship allows you to achieve your Presentations will sell out quickly, so sign on early to secure your talk! • Mobile App objectives before, during, and long Faculty • Hotel Room Keys after the event. Any sponsorship One-on-One Meetings For sponsorship & exhibit • Footprint Trails information, please contact: Select your top prospects from the can be customized to meet your • Conference Tote Bags pre-conference registration list. Companies A-K: company’s needs and budget. • Literature Distribution (Tote Short Courses CHI will reach out to your prospects Ilana Quigley Bag Insert or Chair Drop) Signing on early will allow you to and arrange the meeting for you. Sr Business maximize exposure to qualified A minimum number of meetings • Badge Lanyards Development Manager Sponsor & Exhibit decision-makers. will be guaranteed, depending on • Program Guide Advertisement 781-972-5457 your marketing objectives and [email protected] Opportunities needs. A very limited number of Looking for additional ways to Podium Presentations Companies L-Z: these packages will be sold. drive leads to your sales team? Available Within the Main Agenda! CHI’s Lead Generation Programs Joseph Vacca, M.Sc. Director, Business Development Training Seminar Showcase your solutions to a guar- will help you obtain more target- anteed, targeted audience through a Exhibit ed, quality leads throughout the 781-972-5431 15- or 30-minute presentation during Save $300 Sign up by year. We will mine our database of [email protected] a specific conference program, May 20, 2016 800,000+ life science professionals Agenda breakfast, lunch, or separate from the Exhibitors will enjoy facilitated net- to your specific needs. We guar- main agenda within a pre-conference working opportunities with qualified

Hotel & Travel Demographics for CHI Immuno-Oncology Conferences Information

Registration Information

Click Here to Register Online! Immuno-Oncology COMPANY TITLE GEOGRAPHIC LOCATION DELEGATE TITLE Summit.com Commercial (Biotech + Pharma) 68% USA 70% Scientist/Technologist 38% Academic 17% US Breakdown Executive + Director 36% Healthcare 8% East Coast 60% Professor 11% Financial 3% West Coast 30% Manager 7% Government 2% Midwest 10% Sales & Marketing 4% Services/Societies 1% Europe 18% Other 4% 250 First Avenue Needham, MA 02494 Other (CRO + Press) 1% Asia 7% www.healthtech.com Rest of World 5% Cover Immunology for Drug Discovery Scientists Conference- at-a-Glance Engineering Immunity – Monoclonal Each CHI Training Seminar offers 1.5 days of instruc- Antibody Therapies tion with start and stop times for each day shown Keynotes TRAINING SEMINAR: IMMUNOLOGY above and on the Event-at-a-Glance published in the FOR DRUG DISCOVERY SCIENTISTS MAB #1 - TGN1412 onsite Program & Event Guide. Training Seminars will • Anti-CD28 monoclonal therapy - in- include morning and afternoon refreshment breaks, Instructors: Kevin Bonham, Ph.D., Lecturer, as applicable, and lunch will be provided to all reg- tended to activate Treg cells Microbiology and Immunobiology, Harvard istered attendees on the full day of the class. Faculty Medical School and Matthew Woodruff, Ph.D., • Actually activated all T-cells, caused Postdoctoral Fellow, Emory University cytokine storm in healthy volun- Each person registered specifically for the training sem- In order to detect the presence of potential patho- teers, severe, permanent damage inar will be provided with a hard copy handbook for the seminar in which they are registered. A limited number of gens, the immune system must interact with every Short Courses additional handbooks will be available for other delegates body system and circulate through every tissue. MAB #2 - Natilizumab • Anti α4 integrin -blocks T-cells from entering who wish to attend the seminar, but after these have The weight of the microbial threat has led to the been distributed no additional books will be available. evolution of a unique biological skill set that make brain, highly effective treatment for MS Sponsor & Exhibit the immune system incredibly powerful, but also • Great example of rationally-designed Though CHI encourages track hopping between confer- Opportunities incredibly dangerous. These unique skills and sys- therapy, minimal side effects ence programs, we ask that Training Seminars not be dis- temic reach mean that the immune system touches • Fewer side-effects than most anti-inflam- turbed once they have begun. In the interest of maintain- almost every human disease, either causally or as matory drugs, increased risk for PML ing the highest quality learning environment for Training an avenue for therapy. In this course, we will explore Seminar attendees, and because Seminars are conducted Training Seminar therapeutic approaches that harness our knowledge Receptor/Fc Hybrids - CD4-Fc anti-HIV differently than conference programming, we ask that at- tendees commit to attending the entire program, and not of the immune system to treat human disease. From engage in track hopping, as to not disturb the hands-on vaccines to cancer (not to mention cancer vaccines!) MAB Summary style instruction being offered to the other participants. and diabetes to IBD, we will explore how the immune • Good for inhibiting things, some- Agenda system can be shaped, engineered, and harnessed times can activate by exploring specific examples of current and future • Target must be cell-extrinsic therapeutics, and the immunology behind them. Hotel & Travel Engineering Immunity #2 - CAR-T Cells Dr. Kevin Bonham is a Curriculum Fellow TOPICS INCLUDE: for the Microbiology and Immunobiology Information The Trouble with Neoantigens Department at Harvard Medical School, Introduction to the Unique Biology of and the principal instructor for the the Immune System Pathogen Detection How Many Treatments Does it Masters of Medical Sciences program in and Inflammation (Innate Immunity) Take to Cure Melanoma? Immunology. He received his Ph.D. from Registration Harvard in the lab of Jonathan Kagan, • Cell-intrinsic detection and response Information Molding Immunity - Vaccines where he studied the cell biology and bio- • Local detection, paracrine signaling chemistry of Toll-like Receptor signaling • History of vaccine approach- • Systemic responses and innate immune pattern recognition. es - mostly antibodies Cellular Immunity, Cytotoxicity • Vaccine approaches - better Click Here to • NK-cells adjuvants/better antigens Matthew Woodruff graduated from the Rochester Institute of Technology with a Register Online! • CD8+ T-cells • Vaccine approaches - prime and pull Immuno-Oncology bachelor’s degree in biotechnology, and • Macrophages • Vaccine approaches - skip the received his Ph.D in Immunology from Summit.com • CD4+ T-cells vaccine (gene therapy) Harvard in 2014. He now works as a post- doctoral fellow in Dr. Bali Pulendran’s lab Antibodies Harnessing Immunity - Anti- at the Emory Vaccine Center with a focus • B-cell biology Cancer Approaches on the basic mechanisms of vaccination. • Diversity of antibody function He has published on lymphatic dynamics • Complement fixation Checkpoint Blockade Therapies and flow, lymph node structure and • History function, and the early phases of vaccine Immune System Interactions (The Big Picture) • Targets response. Outside of bench work, he is • Lymphocyte development interested in the use of creative design 250 First Avenue • Antigen presentation (B-cell/T- Cancer Vaccines and non-traditional presentation meth- Needham, MA 02494 cell, APC/T-cell, DC/B-cell) ods to make complex immunological www.healthtech.com concepts relatable to a broad audience. • CD4+ T-cell redux Limitations (Neoantigens, Autoimmunity) MON-TUE | AUGUST 29-30 Cover Immunomodulatory Therapeutic Antibodies for Cancer Conference- Exploring the Evolution of Novel Immunotherapies Based on Checkpoint at-a-Glance Inhibitors, Costimulatory Agonists and Emerging Targets

bination strategies so far have led to even higher Keynotes Recommended Dinner Short Course* 11:00 Tumor-Localized Sponsored by: Targeting the Cancer Mutanome rates of immune events. Most severe toxicities Costimulatory T Cell *Separate registration required, please are manageable with corticosteroids and other Engagement with Bispecific see Short Courses for details immunomodulatory agents. The current data on CD137-Agonists checkpoint blockade toxicities will be reviewed. Faculty Louis Matis, M.D., MONDAY, AUGUST 29 9:30 Coffee Break Senior Vice President, Chief Development Officer, Pieris Pharmaceuticals, Inc. Short Courses 7:30 am Registration & Morning Coffee 10:00 Anti-Hypoxia-A2-Adenosinergic Co- We describe the generation and characteri- Adjuvants to Enable the Full Anti-Tumor zation of the CD137/HER2 and CD137/GPC-3 8:25 Chairperson’s Opening Remarks Capacities of T- and Natural Killer Cells bispecifics designed to promote CD137 cluster- Tariq Ghayur, Ph.D., Distinguished Research During Immunotherapies of Cancer ing in the tumor microenvironment by bridging Sponsor & Exhibit Fellow, AbbVie Bioresearch Center Stephen Hatfield, Ph.D., Research Scientist, CD137- positive T cells with target positive tumor Opportunities New England Inflammation and Tissue cells, thereby providing a potent costimulato- Protection Institute, Northeastern University ry signal to tumor antigen-specific T cells. 8:30 OPENING KEYNOTE The presentation introduces the adenosine-gener- 11:15 Transforming Sponsored by: Training Seminar PRESENTATION: IMMUNOTHERAPY ating CD73 ecto-enzyme as a potential drug target Antibody Discovery with FOR CANCER: THE PROMISE and biomarker of the most resistant human tumors. the Benchling Platform AND CHALLENGES AHEAD In addition, oxygenation agents join antagonists of A2A Adenosine Receptors as novel checkpoint Sajith Wickramasekara, Ronald Herbst, Ph.D., Vice President, R&D; CEO, Benchling Agenda Head, Oncology Research, MedImmune inhibitors that reprogram the TME away from For most antibody discovery R&D, the discovery Immune-evasion is a hallmark of cancer and en- immunosuppression and have promise if used in process is a work in progress. Keeping track of hancement of the anti-cancer immune response combination with existing cancer immunotherapies. experimental results of just antibody leads, much less by targeting checkpoint pathways, such as CTLA- 10:30 The Role of Immune Biomarkers in managing the entire antibody discovery workflow, can Hotel & Travel 4 and PD-1/PD-L1, is showing significant prom- prove difficult. Existing software solutions force users Information ise. However, a subset of patients fails to benefit Offering a Standardized Way of Evaluating the to engage with disparate pieces of software and re- from immune therapy. Going forward it will be in vivo Behavior of Cancer Immunotherapies quire time-consuming and error-prone manual input. key to better understand the immunologic diver- Susan R. Slovin, M.D., Ph.D., Medical Benchling unifies experiment workflows in a single, sity within and across indications, and to identify Oncologist, Genitourinary Oncology Service, collaborative research platform that was co-devel- Registration markers of response (or no response) to therapy Memorial Sloan Kettering Cancer Center oped with scientists, ensuring that cutting-edge Information to further increase the benefit to patients. Major initiatives are ongoing to establish and validate science is never held back by archaic software. In in clinical trials a platform of biomarkers that can this talk we will describe how we work with scientists be used to assess biologic changes and treatment in antibody discovery to empower them to design, responses in solid tumors treated with novel im- Click Here to UNDERSTANDING THE register and optimize antibodies on a single platform. MECHANISMS OF ACTION FOR mune drugs. The identification and relevance of Register Online! biomarkers in trials with immunologic agents can IMMUNOMODULATORY ANTIBODIES 11:30 am End of Morning Session (Delegates Immuno-Oncology vary with the drug used. How to incorporate the may attend session of parallel meeting) Summit.com 9:00 Lessons Learned from Studies metrics of biomarkers into immunotherapy trials and their validation is a major focus of trial design. of Checkpoint Blockade Toxicity 12:00 pm Luncheon Presentation Geoffrey T. Gibney, M.D., Medical Oncologist, (Sponsorship Opportunity Available) Georgetown-Lombardi Comprehensive Cancer Center or Enjoy Lunch on Your Own Recent developments in targeted immune checkpoint blockade have revolutionized treatment approach- 12:30 Session Break es in patients with advanced malignancies. While durable responses are seen, checkpoint therapies are associated with a range of immune-related 250 First Avenue Needham, MA 02494 toxicities that can complicate patient care. Com- www.healthtech.com Cover EMERGING TARGETS AND STRATEGIES are cytotoxic and provide both antigen-linked and TUESDAY, AUGUST 30 FOR CANCER IMMUNOTHERAPY non-linked help. Further, dual costimulated T cells can be triggered to elaborate effector functions not 8:00 am Morning Coffee 1:25 Chairperson’s Remarks only by antigen, but also TCR-independently through Conference- cytokine combinations such as IL-12 or IL-2 plus Adam J. Adler, Ph.D., Professor, at-a-Glance either of the IL-1 family members IL-33 or IL-36. PROTEIN ENGINEERING FOR Immunology, University of Connecticut CANCER IMMUNOTHERAPIES 3:00 Refreshment Break 1:30 Bi- and Multi-Specific Biologics for 8:25 Chairperson’s Opening Remarks Keynotes Cancer Immunotherapy: Selecting Target 3:30 High Dimensional Cell Analysis of John Desjarlais, Ph.D., CSO, Xencor Combinations and Designing Biologics to Early Lung Tumor Immune Contexture Modulate Anti-Tumor T Cell Functions Miriam Merad, M.D., Ph.D., Chair, Cancer 8:30 The Role of Antibody Isotype and Faculty Tariq Ghayur, Ph.D., Distinguished Research Immunology, Oncological Sciences, Tisch Fc Receptor Interactions in Engineering Fellow, AbbVie Bioresearch Center Cancer Institute, Mount Sinai Hospital Cancer Immunotherapies The presentation will discuss how high through- Despite unprecedented clinical response of advanced Stephen Beers, Ph.D., Associate Professor, put functional bioassays have been used to select NSLC to checkpoint blockade, a comprehensive Cancer Immunology and Immunotherapy, Short Courses combinations of mAbs to either the same target understanding of the immune microenvironment University of Southampton (different epitopes) or different targets for generating of early stage NSLC has not been done. Here we Exciting clinical results with checkpoint-blocking mAb dual-specific DVD-Ig molecules with additive and/ will present high dimensional single-cell analysis have revived the belief that the immune system holds or synergistic activity. The talk will also describe of immune changes that occurs in the vicinity of the key to controlling cancer. Here we show that immu- early lung NSCLC. Our results provide a rationale Sponsor & Exhibit the application of new multi-specific formats in nostimulatory mAb can employ multiple mechanisms for testing whether modulation of the lung tumor Opportunities understanding the biology of T cell activation by in tumors, and that the mechanism used depends on immune microenvironment can promote anti-tumor mAb isotype and FcγR availability. These data have co-ligating CD3 and co-receptors and to design immunity, prevent tumor relapse and transform molecules to address specific unmet needs. broad implications for selecting tumor immune targets the outcome of patients with early lung cancer. and engineering immunomodulatory mAb; illustrating Training Seminar 2:00 T Cell Activation and Pre-Clinical the necessity to determine all potential mechanisms of 4:00 Inducing Neo-Antigen Specific T action to maximize activity and potential clinical utility. Anti-Tumor Efficacy of Anti-Lag3 Cells from the Naïve Repertoire Mabs Is Independent of their Lag-3- Marit van Buuren, Ph. D., Scientist, 9:00 Immune Checkpoint Inhibition by Agenda Mhc Class II Blocking Capacity Immunology, Neon Therapeutics High-Affinity Receptor Decoys: Good Saso Cemerski, Ph.D., Associate Principal The recognition of neo-antigens on human cancer Things Come in Small Packages Scientist, Merck Research Laboratories has strongly been connected to the clinical success Aaron Ring, M.D., Ph.D., Assistant Professor, LAG-3 is a MHC-II-interacting receptor that ham- of immune therapies. Neon Therapeutics Inc. aims Immunobiology, Yale University School of Medicine Hotel & Travel pers T cell activation. We assessed the relationship to generate neo-antigen specific vaccines and T Immune checkpoints have largely been therapeuti- Information between anti-LAG-3 antibody-induced efficacy and cell therapies that are tailored for each individual cally targeted using monoclonal antibodies. How- the ability to block LAG-3-MHCII interactions. We patient. Here we will present the platform that Neon ever, non-antibody biologics may offer potential compared the bioactivity of two distinct anti-mLAG-3 has developed to generate a neo-antigen specific T advantages in the context of tumor immunotherapy. antibodies that differ in their ability to block LAG-3- cell product for the use of adoptive cell transfer. This talk will highlight two engineered ultra high-af- Registration MHCII interactions. We demonstrated that anti-LAG-3 finity decoys of PD-1 and SIRPα—checkpoints of the antibody efficacy is not associated with their ability 4:30 Targeting TIM-3 and LAG-3 Information adaptive and innate immune systems, respectively. to disrupt LAG-3-MHCII interaction, suggesting they Jeffrey Hanke, Ph.D., CSO, Tesaro These agents illustrate the potential for small protein could enhance both CD4+ and CD8+ T cell function. Strategies to activate exhausted tumor-specific therapeutics as immunotherapeutics, components T cells, including the use of monoclonal antibod- 2:30 Pathways and Mechanisms of cell-based therapies, and diagnostic agents of Click Here to ies (mAb) that block the negative costimulatory immune function and tumor immunogenicity. Register Online! Engaged by OX40 Plus 4-1BB Dual receptors CTLA-4 and PD-1/PDL1, are proving Costimulation Immunotherapy effective in a number of cancer types. However, Immuno-Oncology Adam J. Adler, Ph.D., Professor, only a subset of patients respond to these ther- Summit.com Immunology, University of Connecticut apies, and resistance is increasingly observed. The role of TIM3 and LAG3 will be discussed. Dual costimulation with CD134 plus CD137 ago- nists elicits powerful therapeutic tumor immunity 5:00 End of Day by priming robust CD8+ CTL, and CD4 T cells that

250 First Avenue Needham, MA 02494 www.healthtech.com Cover 9:30 Targeting Fc Effector Functions to 10:00 Discussion with Session Speakers 11:45 Bispecific Antibodies for T Cell Tumor-Expressed Integrins for Synergistic Recruitment and Dual Checkpoint Blockade Innate and Adaptive Immunotherapy 10:30 Grand Opening Coffee Break in John Desjarlais, Ph.D., CSO, Xencor Conference- K. Dane Wittrup, Ph.D., Carbon P. Dubbs Professor, the Exhibit Hall with Poster Viewing We have optimized a plug-and-play, Fc-containing at-a-Glance Chemical Engineering and Biological Engineering, 11:15 Tumor-Specific Antibodies Engineered bispecific antibody platform with high stability, Massachusetts Institute of Technology efficient production, and antibody-like pharmacoki- to Bind NKG2D Activate both NK and T-Cells Anti-tumor antibodies combined with extended-PK netics. This optimized bispecific format resembles IL-2 leads to significant immunotherapeutic respons- Kyle Landgraf, Ph.D., Senior Scientist, a standard monoclonal antibody, with one of the Fab Keynotes es in large established syngeneic tumors in mice. Discovery Research, AvidBiotics arms replaced by a stability-optimized single-chain In order to extend this approach to tumor types NK and T-cells utilize the NKG2D receptor to destroy Fv (scFv) (scFv-Fab-Fc). We will present application for which specific antibodies are not available, we cancer cells expressing stress ligands. However, of the platform to generate a broad pipeline of CD3 have constructed an Fc fusion to a small knottin tumors deploy strategies to evade this surveillance bispecifics for T cell redirection and dual check- Faculty protein with broad binding specificity to RGD-bind- pathway. Using structure-guided phage display, NKG2D point blockade bispecifics for T cell activation. ing integrins. This pseudo-mAb exhibits strong stress ligands have been engineered as effector efficacy in preclinical models and generates a T-cell domains to convert tumor-specific antibodies into dual 12:15 pm Close of Immunomodulatory dependent protective adaptive immune response. NK/T-cell activators through NKG2D engagement. Therapeutic Antibodies for Cancer Short Courses These antibodies can stimulate IFNγ production and degranulation of NK and T-cells, providing rationale for their use in combination with checkpoint therapies. Sponsor & Exhibit Opportunities

Training Seminar

Agenda PRESENT A POSTER Hotel & Travel Information AND SAVE $50! Registration Information Cambridge Healthtech Institute encourages Reasons you should present your research poster at this attendees to gain further exposure by presenting conference: their work in the poster sessions. To secure a poster • Your poster will be seen by our international delegation, Click Here to board and inclusion in the conference materials, representing leaders from top pharmaceutical, biotech, academic and government institutions Register Online! your abstract must be submitted, approved and your registration paid in full by July 29, 2016. • Receive $50 off your registration Immuno-Oncology • Your poster abstract will be published in our conference Summit.com materials

250 First Avenue Needham, MA 02494 www.healthtech.com MON-TUE | AUGUST 29-30 Cover Oncolytic Virus Immunotherapy Conference- Unlocking Oncolytic Virotherapies: From Science to Commercialization at-a-Glance

Transgene’s portfolio of armed oncolytic Vaccinia Keynotes Recommended Dinner Short Course* UNDERSTANDING Targeting the Cancer Mutanome MECHANISMS OF ACTION Viruses (oVV) by engineering a vector that targets anti-PD1 IgG expression into the tumor. Local con- *Separate registration required, please 9:55 Chairperson’s Remarks centration of virus-encoded antibody was ~10-50 see Short Courses for details times higher than the reference mAb, leading to Fares Nigim, M.D., Massachusetts General Faculty significant improvement of survival in a sarcoma MONDAY, AUGUST 29 Hospital and Harvard Medical School preclinical model. Such results announce the next-gen- eration oVVs, combining immunogenic oncolysis 10:00 Designing Clinical Trials to Elucidate 7:30 am Registration & Morning Coffee with the capacity to deliver complex therapeutic Short Courses Oncolytic Virus Mechanisms-of-Action modalities in the tumor micro-environment. Caroline Breitbach, Ph.D., Vice President, REALIZING THE POTENTIAL OF Translational Development, Turnstone Biologics 12:00 pm Luncheon Presentation Sponsor & Exhibit ONCOLYTIC VIRUS IMMUNOTHERAPY Oncolytic viruses have been shown to target tumors (Sponsorship Opportunity Available) by multiple complementary mechanisms-of-ac- or Enjoy Lunch on Your Own Opportunities 8:25 Chairperson’s Opening Remarks tion, including direct oncolysis, tumor vascular Brian Champion, Ph.D., Senior Vice President, targeting and induction of anti-tumor immunity. 12:30 Session Break R&D, PsiOxus Therapeutics Ltd Phase I/II clinical trials can be designed to validate Training Seminar these mechanisms. Development experience of BIOMARKERS AND IMPROVING 8:30 T-Vec: From Market an oncolytic vaccinia virus and a novel rhabdo- VIRUS ACTIVITY Approval to Future Plans virus oncolytic vaccine will be summarized. Jennifer Gansert, Ph.D., Executive Director, 10:30 T-Stealth Technology Mitigates 1:25 Chairperson’s Remarks Agenda Global Development Lead, Amgen, Inc. Antagonism between Oncolytic Viruses David Kirn, M.D., CEO & Co-Founder, 4D Talimogene laherparepvec (T-VEC) is a modified and the Immune System through Viral Molecular Therapeutics & Adjunct Professor herpes simplex virus type -1 designed to selectively of Bioengineering, UC Berkeley Evasion of Anti-Viral T-Cells Hotel & Travel replicate in tumors and to promote an anti-tumor immune response. T-VEC is approved for metastatic Matthew Mulvey, Ph.D., CEO, BeneVir 1:30 New Biomarkers that Predict Response Information melanoma based on a randomized phase III trial; T Simultaneous combination of OV and immune to Oncolytic Virus Immunotherapy VEC significantly improved durable response rate vs checkpoint inhibitors (ICI) are antagonistic be- Howard L. Kaufman, M.D., FACS, Associate GM-CSF. Data from the pivotal trial and combination cause ICI enhance anti-viral T-cell effector activity Director, Clinical Sciences, Rutgers Cancer studies with checkpoint inhibitors will be presented. and speed OV clearance. BeneVir’s T-StealthTM Registration armed OV mitigate antagonism between OV and Institute of New Jersey; Professor and Information 9:00 Oncolytic Virotherapies ICI because they evade anti-viral T-cells. This Chief, Division of Surgical Oncology, Rutgers as a Single Shot Cure? allows OV and ICI to be administered simultane- Robert Wood Johnson Medical School Stephen J. Russell, M.D, Ph.D., Professor, Mayo Clinic ously over several treatment cycles to maximize T-VEC is the first oncolytic virus approved for the treatment of melanoma, and will soon enter clinical Oncolytic virotherapy is increasingly used as a cancer the likelihood of a synergistic clinical response trials for treatment of other cancers. Further studies Click Here to immunotherapy. However, certain oncolytic virus- using T-VEC in combination with T cell checkpoint es can also mediate wholesale tumor destruction 11:00 Improving Oncolysis and Therapy Register Online! inhibitors are underway and showing promising early independently of an antitumor immune response. with Pharmacologic Modulation results. The identification of predictive biomarkers Immuno-Oncology This is the oncolytic paradigm, where a cytolyt- Antonio Chiocca, Professor & Chairman, of response would be helpful for improving patient Summit.com ic virus with preferential tumor tropism spreads Department of Neurosurgery , Brigham & selection and optimizing therapeutic outcomes. extensively at sites of tumor growth and directly kills Women’s Hospital/ Harvard Medical School We have recently focused on HSV-1 entry receptors the majority of the tumor cells in the body leaving and oncogenic signaling pathways within cancer only a few uninfected tumor cells to be controlled 11:30 Moving Toward Multi- Sponsored by: cells as potential biomarkers of T-VEC response. by the concomitant antitumor immune response. Functionality in Poxvirus- 9:30 Coffee Break Based Oncolytic Virotherapy Eric Quemeneur, Ph.D., Pharm.D., Executive VP and CSO, Transgene 250 First Avenue Poxviruses are powerful immunotherapeutics and Needham, MA 02494 tumor-targeting platforms. We recently expanded www.healthtech.com Cover 2:00 Therapeutic Viral Vector 4:30 PANEL DISCUSSION: ONCOLYTIC Noriyuki Kasahara, M.D., Ph.D., Professor, Evolution: A Robust Platform for the IMMUNOTHERAPY IN THE ERA Departments of Cell Biology and Pathology, Co- Conference- Discovery of Optimized Vectors OF CHECKPOINT BLOCKADE Leader, Viral Oncology Program, University of Miami David Kirn, M.D., CEO & Co-Founder, 4D Robert Coffin, Ph.D., CEO, Replimmune Ltd Pro-drug activator gene therapy with retroviral at-a-Glance replicating vectors is tumor-selective, and can lead Molecular Therapeutics; Adjunct Professor, • Is there a future for single agent oncolytic to development of anti-tumor immunity. Ascend- Bioengineering, University of California, Berkeley immunotherapy, if so in what clinical context? • Is clinically effective intravenous dosing ing dose Phase I trials by Tocagen Inc. in recurrent Therapeutic virus vectors hold great promise for high-grade glioma demonstrated favorable safety with oncolytic immunotherapies, as single Keynotes cancer gene and immunotherapy. However, novel and tolerability, intratumoral virus spread, radio- agent or in combination, achievable? vectors with improved efficacy are needed. Thera- graphic responses, and survival surpassing historical peutic Vector Evolution is a discovery platform from • What is next for the development of the next benchmarks. Based on these results, a randomized which optimized and proprietary viral vectors can be generation of oncolytic immunotherapies? controlled Phase II/III trial is now underway. Faculty identified with beneficial characteristics of interest. 10:00 Seprehvir, an Icp34.5 Deleted OHSV 2:30 Enhancing Oncolytic Virus Activity 5:00 End of Day with Both Direct and Covert Modes of Action by Engineering of Artificial MicroRNAs Short Courses Joe Conner, Ph.D., CSO, Virttu Biologics John Bell, Ph.D., Senior Scientist, Centre for Innovative TUESDAY, AUGUST 30 Seprehvir, an oncolytic HSV, is a complex biologic with Cancer Research, Ottawa Hospital Research Institute, multi-mechanistic modes of action. Lytic cytotoxicity, Professor, Departments of Medicine and Biochemistry, 8:00 am Morning Coffee induction of Th1 cytokines/chemokine responses, Sponsor & Exhibit Microbiology & Immunology, University of Ottawa recruitment of innate and adaptive immune cells and Opportunities We have devised a novel strategy to enhance the changes in the tumor microenvironment can enhance ability of oncolytic viruses to infect malignant TRANSLATIONAL AND CLINICAL UPDATES therapeutic efficacy in combination with other an- cells by expressing artificial microRNAs (amiR- ti-cancer agents. How these modes of action intersect NAs) from the oncolytic virus genome. We have 8:25 Chairperson’s Opening Remarks with PD-1 checkpoint inhibitors, CAR T cells and small Training Seminar screened a variety of amiRNAs and identified a molecule targeted therapies will be discussed. number that enhance virus replication within tu- 8:30 Phase I of Intravenous Vcn-01 mour but not normal cells. The characterization of in Patients with Advanced Cancer: 10:30 Grand Opening Coffee Break in these miRNAs and their targets will be discussed. Update on Clinical & Biologic Data the Exhibit Hall with Poster Viewing Agenda 3:00 Refreshment Break Manel Cascallo, Ph.D., Co-Founder, President and CEO, VCN Biosciences 11:15 Virus Manufacturing Comes of 3:30 Immuno-Oncolytic Viruses A first-in-human Phase I dose escalation study of Age: Turning Bugs into Features Hotel & Travel as Cancer Therapies intravenous administration of VCN-01 (an oncolyt- Anthony Davies, Ph.D., COO, 4D ic adenovirus with RB tumour-targeting properties Molecular Therapeutics Stephen Thorne, Ph.D., Professor and Scientific Information and expressing hyaluronidase) with or without Viruses destroy the host in which you’re trying to Advisor, Inventor, Western Oncolytics gemcitabine and Abraxane is ongoing for patients produce them and then must be separated from all Oncolytic viruses primarily act as immunotherapies, with advanced solid tumours including pancreat- components of those cells. Many solutions to these yet most vectors still rely on the virus’ inherent immune Registration ic cancer. Dose dependent tolerability data and challenges have been invented since the earliest activation, often coupled to single cytokine transgene VCN-01 levels in different biological samples (in- production of viral vaccines in primary cells obtained Information expression. However, for optimal activity they will need cluding blood and tumour biopsies) are available. directly form animals. But few have proven amenable to overcome the tumor¹s immunosuppressive microen- to cost-effective, compliant and scaleable operation. vironment, to raise anti-tumor CTL and allow repeated 9:00 Reolsyin: A Clinical Update of a Directed systemic delivery. Approaches to achieve all of these Cytotoxic Agent and Immune Modulator 11:45 Manufacturing Large Enveloped activities in a single vector are being developed. Click Here to Brad Thompson, Ph.D., CEO, Oncolytics Biotech Oncolytic Viruses for Human Clinical Trials Register Online! 4:00 Arming the Oncolytic Virus REOLYSIN was initially investigated for its potential Mark J. Federspiel, Ph.D., Professor and Director, Immuno-Oncology Enadenotucirev to Develop Tumor-Localized as a selective cytotoxin. However, recent research Viral Vector Production Laboratory, Mayo Clinic shows that it also functions as an immune modula- Summit.com Combination Immunotherapeutics The large-scale production and purification of larger tor. This dual mechanism of action for a single viral enveloped oncolytic viruses are particularly challeng- Brian Champion, Ph.D., Senior Vice President, agent suggests that the potential of viral therapies ing. We have developed enveloped virus GMP produc- R&D, PsiOxus Therapeutics Ltd. may be broader than previously anticipated. tion processes using suspension cells in combination We have developed a systemically deliverable, onco- with gentle but effective purification using hollow lytic adenoviral platform for directing efficient and 9:30 Retroviral Replicating Vectors for fiber tangential flow filtration that result in greater selective local production of a combination of biother- Cancer-Selective Immuno/Gene Therapy: than 99.5% removal of contaminants and greater than apeutic agents selectively within the tumor. This has Translational and Clinical Update 100-fold increases in final infectious virus titers. the potential for enhanced efficacy while reducing side effects by limiting systemic exposure. Up to three sep- 12:15 pm Close of Oncolytic 250 First Avenue arate biomolecules can be encoded in the same virus Virus Immunotherapy Needham, MA 02494 without affecting oncolytic properties of the virus. www.healthtech.com TUE-WED | AUGUST 30-31 Cover Rational Combination Cancer Immunotherapy Conference- A Forward-Looking View of the Science and Strategies that Will Inform the at-a-Glance Discovery and Development of Effective Immunotherapy Combinations

either a T cell-inflamed or non-T cell-inflamed tumor Keynotes Recommended Dinner Short Course* 8:30 Breaking the Suppressive Myeloid Barrier Targeting the Cancer Mutanome microenvironment. This approach also facilitates a to Overcome Checkpoint Blockade Resistance framework for interrogating molecular mechanism of *Separate registration required, please Michael A. Curran, Ph.D., Assistant Professor, immune exclusion mediating non-inflamed tumors. see Short Courses for details Immunology; Scientific Director, ORBIT Faculty 2:20 Programming DCs in situ Platform MD Anderson Cancer Center TUESDAY, AUGUST 30 for Cancer Vaccination While blockade of T cell immune checkpoint mol- ecules such as CTLA-4 and PD-1 has dramatically Omar Ali, Ph.D., Staff Scientist, Wyss Institute for improved therapeutic outcomes in metastatic Biologically Inspired Engineering, Harvard University Short Courses 12:00 pm Registration melanoma and lung cancer, many other cancers The innate components required to mediate effective such as those of the pancreas, prostate, and colon 1:15 Chairperson’s Opening Remarks vaccination against weak tumor-associated antigens (MSI-low) fail to respond. We find that suppressive Arthur M. Krieg, M.D. CEO, remain unclear. We utilize three-dimensional and myeloid cells play a critical role in mediating this Sponsor & Exhibit Checkmate Pharmaceuticals macroporous, polymeric cancer vaccines incorporat- resistance, and that through their disruption these Opportunities ing different classes of TLR adjuvants to induce tumor cancers can be sensitized to checkpoint blockade. regression and protection in order to identify dendritic cell subsets and cytokines critical to this efficacy. 1:20 KEYNOTE PRESENTATION: 9:00 Novel Combinations of Vaccine-induced tumor regression correlated to local Immunotherapeutics Based on Preclinical Training Seminar SELECTING PD-L1/PD-1 CD8(+) DC and pDC numbers, IL-12, and G-CSF con- IMMUNOTHERAPY COMBINATIONS centrations regardless of the incorporated adjuvant. Modeling and Clinical Biomarker Analysis Edward Cha, M.D., Ph.D., Associate Christopher R. Heery, M.D., Director, 2:50 Discussion with Session Speakers Medical Director, Cancer Immunotherapy Clinical Trials Group, Laboratory of Tumor Immunology, Center for Cancer Research Agenda Franchise, Genentech 3:20 Refreshment Break in the This talk will discuss examples of clinical trial design Although targeted inhibition of the PD-L1 path- Exhibit Hall with Poster Viewing way enhances anti-tumor immunity, not all pa- based on integration of preclinical modeling and tients achieve benefit from single-agent immuno- pharmacokinetic and pharmacodynamic analysis of Hotel & Travel early stage trials. The focus will be on integration of therapies. Determining and prioritizing effective 4:00 PLENARY KEYNOTE SESSION Information combinations will rely on further understanding new findings as an iterative process toward optimal See Keynotes for details. trial design to achieve maximal clinical benefit. of the mechanisms that drive immune resistance across indications and individual patients.

Registration 5:30 Welcome Reception in the 9:30 FEATURED PRESENTATION: Information Exhibit Hall with Poster Viewing SUMMARY OF KEY CLINICAL CONSIDERATIONS IN DESIGNING COMBINATION TRIALS IMMUNOTHERAPY COMBINATIONS 5:30 Dinner Short Course Registration* PRESENTED AT ASCO *Separate registration required, please 1:50 Rational Combination Immunotherapy Paul Rennert, Ph.D., President & Click Here to see Short Courses for details CSO, Aleta Biotherapeutics Inc. Development Stratified by the Presence ASCO 2016 will give us new insights into diverse Register Online! or Absence of the T Cell-Inflamed Immuno-Oncology WEDNESDAY, AUGUST 31 and interesting advances in oncology therapeu- Tumor Microenvironment tics. I will report on the top studies of interest Summit.com Jason J. Luke, M.D., FACP, Assistant Professor, in the following areas: novel immune check- 8:00 am Morning Coffee Medicine, Melanoma and Developmental Therapeutics points and checkpoint combinations; immune Clinics, University of Chicago Medical Center checkpoint combinations with other therapies, Tumors can be categorized by gene expression CLINICAL UPDATES targets in the tumor microenvironment, CAR T based on the presence or absence of a T cell-in- and TCR therapies, and other studies that enrich flamed tumor microenvironment, and this cor- 8:25 Chairperson’s Remarks our understanding of immuno-oncology as a relates with either response or lack of response to Christopher R. Heery, M.D., Director, broad-based discipline for cancer therapy. immune-checkpoint blockade. Categorization of Clinical Trials Group, Laboratory of Tumor these biologically distinct subsets suggests ratio- Immunology, Center for Cancer Research 250 First Avenue nal immunotherapy combinations directed toward Needham, MA 02494 www.healthtech.com Cover 10:00 Enhancement of Sponsored by: Ventures, J&J Innovation Center Boston like ADCs will remain important treatment modali- Immune Responses with a Taylor Schreiber, M.D., Ph.D., CSO, Heat Biologics, Inc. ties. Understanding how these could be combined Well-Tolerated Selective Elena Spanjaard, Ph.D., Director, Worldwide Research or sequenced with immunotherapy to transform cancer care is crucial. Pfizer’s immunotherapies & Development, Regulatory Affairs, Pfizer Conference- TLR3 Agonist and Potential in the clinic include those targeting PD-1, PD-L1, at-a-Glance for I-O Combination 12:45 pm Luncheon Presentation CTLA-4, OX-40, CD137, CCR2, and MSCF. The ratio- Christopher F. Nicodemus, M.D., FACP, nale for combinatorial strategies will be discussed. President & CSO, AIT Strategies (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own 3:30 Refreshment Break with Keynotes Despite dramatic advances with checkpoint inhibitors, the majority of cancer patients fail Exhibit and Poster Viewing monotherapy. Rintatolimod is a selective TLR3 1:15 Session Break agonist with >900 patient dosing experience. 4:15 Immunotherapy in Combination Faculty Evidence will be reviewed that rintatolimod: IMMUNOTHERAPY COMBINATION with Novel Tumor Vaccines • Modulates the human tumor microenvironment STRATEGIES Craig L. Slingluff, Jr., M.D., Professor, Surgery, • Restores cellular immune responses University of Virginia School of Medicine • Synergizes with checkpoint inhibi- 1:55 Chairperson’s Remarks New approaches to cancer vaccines may use neoanti- Short Courses tion in animal tumor models Paul Rennert, Ph.D., President & CSO, gens, novel antigen formulations, or modified delivery • Has monotherapy activity in melano- Aleta Biotherapeutics Inc. systems. Promising findings support vaccines target- ma and renal cell carcinoma ing CD4+ helper T cells, and new approaches to in situ 2:00 Next-Generation Biomarkers for the Era vaccination show promise. Novel vaccine adjuvants Sponsor & Exhibit • Currently in human cancers trials as a component of immunotherapy of Combination Cancer Immunotherapy may augment T cell responses, and combinations with Opportunities David Kaufman, Ph.D., Executive Director, Clinical a range of checkpoint blockade molecules or other • IP protection to 2028 systemic therapy agents may favorably modulate Oncology, Merck Research Laboratories immune responses to vaccines and to human cancers. 10:30 Coffee Break in the Exhibit A variety of other agents may have additive or Training Seminar Hall with Poster Viewing synergistic activity in combination with PD-1 4:45 Novel Combination Immunotherapy checkpoint blockade. As such regimens advance, Strategies to Optimize T Cell it will be critically important to understand how 11:15 Cancer Immunotherapy: Responses Against Cancer Immunomodulatory Approaches Beyond PD-1 to direct the right combinations to patients who stand to benefit most from them. Next-generation Howard L. Kaufman, M.D., FACS, Associate Agenda Andrea van Elsas, Ph.D., CSO, Aduro biomarkers are beginning to provide insight into Director, Clinical Science, Chief Surgical Officer, Biotech Europe, The Netherlands fundamental aspects of tumor cell and immune Rutgers Cancer Institute of New Jersey T cell checkpoint inhibitors set a clinical paradigm biology that are relevant for a precision medicine The remarkable success of T cell checkpoint inhib- Hotel & Travel providing significant benefit to patients diagnosed approach to cancer immunotherapy combinations. itors has highlighted the importance of promoting with advanced cancer. Despite success, the majority Information activation and preventing suppression of T cells for of patients do not respond to PD-1, PD-L1 or CTLA-4 2:30 Inhibition of Immune Checkpoints the treatment of cancer. This presentation will discuss blockade. Raising the number of patients benefiting and Vascular Endothelial Growth Factor as the central importance of T cells within the tumor mi- from cancer immunotherapy requires novel thera- Combination Therapy for Metastatic Melanoma croenvironment, highlight some of the more promising peutic approaches aimed at these non-responders, combinations in development and provide recommen- Registration for instance using novel immunomodulatory anti- Patrick Alexander Ott, M.D., Ph.D., Assistant Professor, Medicine, Dana-Farber Cancer Institute dations for how to select the most promising immuno- Information bodies and combination with active immunization. therapy agents for combination regimens. Emerging evidence indicates that immunotherapy 11:45 Panel Discussion: Best Practices for can lead to immune-mediated vasculopathy in the 5:15 Enhancing the Efficacy of Organizations and Academic Labs Entering tumor. While the inhibition of angiogenesis through Checkpoint Inhibition with a TLR9 Agonist Click Here to the Cancer Immunotherapy Space targeting of vascular endothelial growth factor (VEGF) has been used successfully for the treat- Delivered in a Virus-Like Particle Moderator: Llew Keltner, M.D., Ph.D., CEO, EPISTAT Register Online! ment of cancer the mechanisms of its anti-tumor Arthur M. Krieg, M.D. CEO, Immuno-Oncology The scientific potential of immunotherapy combina- activity remain poorly understood. Initial studies of Checkmate Pharmaceuticals Summit.com tions is vast, and the clinical successes in this space the complex relationship between angiogenesis, Checkpoint inhibitors can induce durable remissions have attracted significant numbers of large and small VEGF signaling and the immune system suggest in patients with advanced malignancies that are players to the field. Our panel will dissect the most that the combination of immune checkpoint block- immunologically “hot” (have a type I IFN signature important scientific and strategic considerations for ade with angiogenesis inhibition has potential. and CD8 T cell infiltrates) but they are rarely effective those wanting to participate in these collaborations in the treatment of immunologically “cold” tumors. and offer audience members the opportunity for 3:00 Rationale for Combinatorial Intratumoral injection of a TLR9 agonist CpG-A oli- focused feedback from experts in business, regulato- Immunotherapy Approaches gonucleotide is expected to convert “cold”, check- ry, scientific, healthcare and dealmaking functions. Alex Morozov, M.D., Ph.D., Senior Medical point-unresponsive tumors into “hot” tumors, resulting Panelists: Director and Global Clinical Lead, Pfizer in an increased response rate to combination therapy. Konstantin M. Linnik, Ph.D., Partner, Intellectual 250 First Avenue Immunotherapy is poised to become an integral part Property, Nutter, McClennen & Fish, LLP 5:45 Close of Rational Combination Needham, MA 02494 of the cancer treatment paradigm. Cytotoxics, TKIs, www.healthtech.com Kuldeep Neote, Ph.D., Senior Director, New other small molecules, and non-IO large molecules Cancer Immunotherapy TUE-WED | AUGUST 30-31 Cover Personalized Immunotherapy Conference- Personalized Oncology in the Genomic Era: Expanding the Druggable Space at-a-Glance 102 and NEO-201 were candidates that demonstrated PERSONALIZED IMMUNOTHERAPY the ability to bind to colon cancer vs. normal tissue. WITH CANCER VACCINES Recommended Dinner Short Course* Keynotes 2:20 PD-1 Blockade in Tumors with Bispecific Antibody Development for Immunotherapy 8:25 Chairperson’s Remarks Mismatch-Repair Deficiency *Separate registration required, please Ravi Madan, M.D., Clinical Director, Genitourinary see Short Courses for details Luis Alberto Diaz, M.D., Associate Professor, Malignancies Branch, National Cancer Faculty Oncology, Johns Hopkins Sidney Kimmel Institute, National Institutes of Health Comprehensive Cancer Center TUESDAY, AUGUST 30 Somatic mutations have the potential to encode 8:30 Presentation to be Announced “non-self” immunogenic antigens. Tumors with Short Courses 12:00 pm Registration a large number of somatic mutations due to mis- 9:00 Developing Therapeutic Cancer match-repair defects appear to be highly sus- Vaccine Strategies for Prostate Cancer ceptible to immune checkpoint blockade. This TUMOR NEOANTIGENS FOR Ravi Madan, M.D., Clinical Director, Genitourinary PERSONALIZED IMMUNOTHERAPY presentation will summarize the clinical and ge- Sponsor & Exhibit nomic data of using mutations as neoantigens. Malignancies Branch, National Cancer Opportunities Institute, National Institutes of Health 1:15 Chairperson’s Opening Remarks 2:50 In situ Vaccination for Lymphoma The development of immunotherapy strate- Pramod K. Srivastava, M.D., Ph.D., Professor, Joshua Brody, M.D., Director, Lymphoma gies has become the primary focus in oncolo- Immunology and Medicine, Director, Carole Immunotherapy Program, Icahn School gy. This lecture will provide prostate cancer as Training Seminar and Ray Neag Comprehensive Cancer Center, of Medicine at Mount Sinai a template to demonstrate synergies between University of Connecticut School of Medicine immune-based therapies and chemotherapy, ra- Prior ex vivo combinations of dendritic cells (DC) diopharmaceuticals and hormonal therapies. 1:20 Basics of Personalized Immunotherapy: with tumor antigens have yielded immunologic and clinical responses. Intratumoral immunomodula- 9:30 Getting Very Personal: Fully Agenda What Is a Good Antigen? tion may bypass the need for ex vivo production of Pramod K. Srivastava, M.D., Ph.D., Professor, vaccine. In situ vaccination combines: intratumoral Individualized Tumor Neoantigen-Based Immunology and Medicine, Director, Carole Flt3L to recruit DC, low dose radiotherapy to load DC Vaccine Approaches to Cancer Therapy and Ray Neag Comprehensive Cancer Center, with tumor antigens, and intratumoral TLR agonist to Karin Jooss, Ph.D., CSO, Gritstone Oncology Hotel & Travel University of Connecticut School of Medicine activate tumor-antigen-loaded DC. Preliminary results Genetic instability in tumors generates tumor-spe- Information The definition of host-protective immunogenic demonstrate DC recruitment and activation, system- cific neoantigens which have been identified as antigen(s) of any human cancer of non-viral origin is ic tumor regressions, and induction of neoantigen the targets of new T cells in patients responding to still an enigma. New approaches in cancer genomics specific CD8 T cell responses after vaccination. checkpoint inhibitor therapy. Predicting neoantigens and bioinformatics are now offering a plethora of by sequencing routine clinical biopsy material, and Registration candidate antigens, whose role in cancer immunity, 3:20 Refreshment Break in the then incorporating them into therapeutic cancer Information and specifically in host-protective cancer immunity, is Exhibit Hall with Poster Viewing vaccines is an attractive concept being developed by under extensive testing. Outlines of some broad rules Gritstone Oncology. The complexities of neoantigen are emerging and some of these shall be discussed. prediction will be discussed, together with insights 4:00 PLENARY KEYNOTE SESSION into how vaccine vectors are selected and designed. Click Here to 1:50 Novel Antibodies against See Keynotes for details. Immunogenic Neoantigens 10:00 Approaches to Assess Sponsored by: Register Online! Tumor Mutation Load for Immuno-Oncology Philip M. Arlen, M.D., President & CEO, Precision Biologics, Inc. Selecting Patients for Cancer Summit.com 5:30 Welcome Reception in the Two novel antibodies, NEO-102 (ensituximab) and NEO- Exhibit Hall with Poster Viewing Immunotherapy 201, were developed from an allogeneic colorectal can- John Simmons, Ph.D., Manager, Research cer vaccine that had previously shown activity in pa- 5:30 Dinner Short Course Registration* Services, Personal Genome Diagnostics tients with metastatic colorectal cancer This vaccine *Separate registration required, please Tests to identify patients who are most likely to benefit was derived from an immunogenic component of the see Short Courses for details from cancer immunotherapies are urgently needed. cell membrane from pooled surgical specimens from Here we discuss PGDx approaches to assess tumor both primary and metastatic colon cancer. Patients mutation load as a potential predictor of clinical bene- who benefited from the vaccine in the prior clinical WEDNESDAY, AUGUST 31 fit for checkpoint inhibitors in multiple cancer types. trial produced and sustained high levels of serum IgG 250 First Avenue against the vaccine. Several thousand candidate anti- 8:00 am Morning Coffee 10:30 Coffee Break in the Exhibit Needham, MA 02494 bodies were screened against this vaccine and NEO- www.healthtech.com Hall with Poster Viewing Cover 11:15 eVLP Delivery of Novel Foreign Antigens these therapeutics continue to be defined. Additionally, Bellicum Pharmaceuticals has developed Elicits Polyvalent Anti-Tumor Immunity understanding tumor and patient/host heterogeneity a suite of synthetic ligand-inducible is desired in order to optimize personalized medicine. Adam Buckley, Vice President, Business switches to rapidly and rigorous- Conference- Development, VBI Vaccines ly regulate T cell therapies. 2:30 Dendritic Cells: Personalized Cancer These potent switches address both at-a-Glance Vaccines and Inducers of Multi-Epitope- 11:45 Immunotherapy Using Ad5 safety and anti-tumor efficacy Specific T Cells for Adoptive Cell Therapy [E1-, E2b-] Vector Vaccines in the and promise to further expand the Pawel Kalinski, M.D., Ph.D., Professor, reach of immunotherapy. Cancer MoonShot 2020 Program Keynotes Surgery, Immunology, and Bioengineering, Frank R. Jones, Ph.D., Chairman & University of Pittsburgh School of Medicine, 4:45 Long-Term Relapse-Free Survival CEO, Etubics Corporation University of Pittsburgh Cancer Institute of Patients with Acute Myeloid Leukemia The Cancer MoonShot 2020 project intends to design, Conditions of dendritic cell (DC) maturation affect (AML) Receiving a Telomerase- Engineered Faculty initiate and complete randomized clinical trials at all their ability to cross-present cancer cell-derived Dendritic Cell Immunotherapy stages of cancer in up to 20 tumor types in as many as antigens and induce clonal expansion and effector 20,000 patients by the year 2020. Etubics is participat- Jane Lebkowski, Ph.D., President & CSO, Research functions of responding T cells. We will discuss the and Development, Asterias Biotherapeutics ing in the Cancer MoonShot 2020 program by provid- pathways of DC maturation which promote their There are few treatment options for patients with Short Courses ing its proprietary viral platform, known as Ad5 [E1-, preferential interaction with naïve, memory and intermediate and high risk AML, and remission and E2b-] as a treatment agent in several of the program’s effector T cells, cross-presentation of antigens from relapse rates are dismal, especially in patients ≥ 60 immunotherapeutic vaccination initiatives and trials. dead cancer cells, and induction of large numbers years old. A Phase II clinical trial was conducted in of type-1 CD4+ and CD8+ T cells specific for multi- 12:15 pm Sponsored Presentations subjects with AML to assess a dendritic cell immuno- Sponsor & Exhibit ple tumor-associated antigens ex vivo and in vivo. Opportunities (Opportunities Available) therapy (ASTVAC1) engineered to express a modi- 3:00 Mesothelin-Targeted CAR T-Cell fied form of telomerase that is processed through 12:45 Luncheon Presentation Sponsored by: both the MHC Class I and II antigen presentation Therapy for Solid Tumors pathways. The results suggest that immunother- to be Announced Prasad S. Adusumilli, M.D., FACS, Deputy Chief Training Seminar apy with AST-VAC1 is safe, can stimulate immune Robert G. Petit, Ph.D., of Translational & Clinical Research, Thoracic responses to telomerase, and may extend relapse-free Executive Vice President Surgery, Memorial Sloan-Kettering Cancer Center survival even in patients with high risk AML. & CSO, Advaxis Immunotherapies Mesothelin, a cell-surface antigen, provides an exciting Agenda prospect based on its higher expression in a major- 5:15 Activated and Exhausted Tumor Infiltrating 1:15 Session Break ity of solid tumors (estimated annual incidence of B Cells in Non-Small Cell Lung Cancer 340,000 and prevalence of 2 million patients in the Patients Present Antigen and Influence the PERSONALIZED CELL THERAPY U.S.), limited expression in normal tissues and its Phenotype of CD4 Tumor Infiltrating T Cells Hotel & Travel association with tumor aggressiveness. CAR T-cell 1:55 Chairperson’s Remarks therapy with second generation mesothelin-tar- Tullia Bruno, Ph.D., Research Assistant Professor, Information Immunology, University of Pittsburgh Andrew M. Evens, D.O., Professor and Chief, geted CARs has been translated to clinical trials The focus of immunotherapy has been on subsets of Hematology/Oncology, Tufts University School targeting mesothelioma, non-small cell lung cancer, CD8 and CD4 tumor infiltrating lymphocytes (TILs), of Medicine; Director, Tufts Cancer Center triple-negative breast cancer, and other solid tumors. Registration however, tumor infiltrating B cells (TIL-Bs) have been 2:00 Integration of Natural Killer-Based 3:30 Refreshment Break with reported in tertiary lymphoid structures (TLS) with Information Exhibit and Poster Viewing CD4 TILs, and both TIL-Bs and TLS correlate with Therapy into the Treatment of Lymphoma NSCLC patient survival. While TIL-Bs have been Andrew M. Evens, D.O., Professor and Chief, 4:15 Synthetic Regulation of T Cell Therapies identified in NSCLC patients, their function in the Hematology/Oncology, Tufts University School Adds Safety and Enhanced Efficacy to tumor microenvironment has been understudied with of Medicine; Director, Tufts Cancer Center no focus on their role as antigen presenting cells Click Here to Previously Unpredicted Therapies Register Online! Targeting signaling pathways or epitopes with small (APCs) and their influence on CD8 and CD4 TILs. molecules and antibody-based immunotherapeu- David M. Spencer, Ph.D., CSO, Here, we demonstrate that TIL-Bs can efficiently Immuno-Oncology tic agents is a leading strategy for cancer therapy. Bellicum Pharmaceuticals present antigen to CD4 TILs and influence CD4 TIL Summit.com Promising immunotherapy agents being examined for CAR- and TCR-based T cell therapies have phenotype depending on their exhaustion profile. the treatment of lymphoma include monoclonal anti- had some spectacular successes in a hand- bodies, immunomodulatory agents, PD-1 inhibitors, ful of malignancies, but safety and efficacy 5:45 Close of Personalized chimeric antigen receptor (CAR) T-cells, and NK-based concerns still impede broader adop- Immunotherapy Conference therapies. The optimum combinations or sequences of tion of these new technologies.

250 First Avenue Needham, MA 02494 www.healthtech.com TUE-WED | AUGUST 30-31 Cover Preclinical & Translational Immuno-Oncology Conference- Predictive Preclinical Models for Cancer Immunotherapy at-a-Glance

Keynotes Recommended Dinner Short Course* 2:20 Understanding the Tumor 8:30 Augmenting Anti-Tumor Immune Response Bispecific Antibody Development for Immunotherapy Microenvironment: Insights from by Targeting the Notch or Wnt Pathways *Separate registration required, please Studying Mouse Tumor Models in Combination with PD1 Axis Blockade see Short Courses for details Zhao Chen, Ph.D., Investigator III, Exploratory Immuno- Jakob Dupont, M.D., Senior Vice President Faculty Oncology, Novartis Institutes for BioMedical Research & CMO, OncoMed Pharmaceuticals TUESDAY, AUGUST 30 The success of cancer immunotherapy brings our attention to the non-tumor components of cancer. 9:00 Value of QSP (Quantitative Systems The cross-talks between different cell populations Pharmacology) in silico Physiological Models Short Courses 12:00 pm Registration within the tumor microenvironment (TME) likely in Drug Discovery and Development dictate the efficiency and efficacy of anti-tumor Oliver Ghobrial, Ph.D. PRECLINICAL MODELS FOR immune response. Yet, what governs the immune Sponsor & Exhibit IMMUNO-ONCOLOGY system status within a given tumor remains unclear. 9:30 A Modified Developmental and Using mouse cancer models, we are able to address Reproductive Toxicity Testing Strategy Opportunities 1:15 Chairperson’s Opening Remarks specific questions including the roles of tumor for Cancer Immunotherapy Douglas Linn, Ph.D., Senior Scientist, genotypes and tumor location in shaping up TME. Rodney Prell, Ph.D., DABT, Principal Scientist/ In Vivo Pharmacology, Merck 2:50 Preclinical Models of Immuno- Toxicologist, Safety Assessment, Genentech Training Seminar 1:20 Development of Therapeutic Antibodies Oncology: How Do They Translate? The tumor microenvironment establishes several inhibitory pathways that lead to suppression of the to Immune Checkpoint Receptors and Karuppiah Kannan, Ph.D., Associate Director, Cancer Pharmacology, Takeda Pharmaceuticals International local immune response, which is permissive for Their Validation in Humanized Mice growth. Similar pathways have also evolved during Agenda Ella Ioffe, Ph.D., Associate Director, Immune- 3:20 Refreshment Break in the pregnancy as a way to protect the fetus from im- Oncology, Regeneron Pharmaceuticals Exhibit Hall with Poster Viewing mune-mediated rejection. Therefore, cancer im- PD-1 and LAG-3 are immune checkpoint receptors munotherapies designed to enhance the immune Hotel & Travel on effector T cells, which when activated can allow response against the tumor may have the undesired tumors to escape immunosurveillance. Regeneron 4:00 PLENARY KEYNOTE SESSION effect of increasing immune responses to allo-anti- Information has generated fully human monoclonal antibodies gens expressed by the fetus. Reproductive toxicity See Keynotes for details that block (human) PD-1 and LAG-3 function. How- studies are meant to reveal any potential effects on ever, since these antibodies do not block murine mammalian reproduction at various stages and are proteins, we engineered mice expressing humanized used to inform the potential risk to women that are or Registration ectodomains of PD-1 and LAG-3 from the murine loci, 5:30 Welcome Reception in the may become pregnant, while receiving treatment. Information to allow in vivo testing of these clinical antibodies. Ro- Exhibit Hall with Poster Viewing 10:00 Understanding the Sponsored by: bust anti-tumor efficacy of anti-PD-1 (REGN2810) and anti-LAG-3 in humanized mice supports their clinical 5:30 Dinner Short Course Registration* Impact of Animal development in combination cancer immunotherapy. *Separate registration required, please Vendors and the Microbi- Click Here to see Short Courses for details ome—in Tumor Progression and Treatment— Register Online! 1:50 Applying Preclinical Immuno-Oncology in a Model of Metastatic Breast Cancer Mouse Models to Guide Decisions in the Clinic Immuno-Oncology WEDNESDAY, AUGUST 31 Britnie James, Ph.D., Lead Scientist, Research Douglas Linn, Ph.D., Senior Scientist, Summit.com & Development, MD Biosciences In Vivo Pharmacology, Merck 8:00 am Morning Coffee Dysbiosis can correlate with the predisposition The success of immunotherapies such as and progression of cancer. Animal vendor differ- checkpoint inhibitors has changed the way TRANSLATIONAL RESEARCH ON ences in the microbiome can impact immuno- cancers are being treated. Preclinical COMBINATIONAL IMMUNOTHERAPY logical and cellular functions. We have examined immuno-oncology mouse models provide tremen- whether animals from different vendors, with dous value to shaping clinical strategies given that 8:25 Chairperson’s Remarks discrete microbiomes, would present with differ- countless potential combinations exist with other Oliver Ghobrial, Ph.D., Principal Scientist, ent disease progression and therapy responses immunotherapies, radiation, and/or standards Translational Informatics, Sanofi in a murine model of metastatic breast cancer. of care. This talk will provide an overview of how 250 First Avenue immuno-oncology mouse models serve a critical 10:30 Coffee Break in the Exhibit Needham, MA 02494 www.healthtech.com role in guiding treatment options at the bedside. Hall with Poster Viewing Cover NOVEL IN VITRO MODELS FOR NEW TARGETS FOR medulloblastoma in response to interferon-gamma, IMMUNOTHERAPY DISCOVERY CHECKPOINT INHIBITORS and can result in efficient tumor elimination by normal host immune response. These exciting findings Conference- 11:15 Testing Efficacy of Immunotherapy 1:55 Chairperson’s Remarks and their clinical implications will be discussed. at-a-Glance in vitro: Primary 3D Co-Cultures of Xingxing Zang, Ph.D., Associate Professor, 3:30 Refreshment Break with Tumor Cells and T Lymphocytes Microbiology and Immunology & Medicine, Exhibit and Poster Viewing Christian Schmees, Ph.D., Head of Tumor Albert Einstein College of Medicine Biology, Molecular Biology Department, Keynotes 2:00 Tumor Associated Myeloid Cells Can PATHWAY DISCOVERY FOR NMI Natural and Medical Sciences Institute COMBINATION THERAPY at the University of Tübingen Be Rendered Dysfunctional by the Tumor Microenvironment through Expression of TIM- The development of more efficient approaches in 4:15 Immune Modulation: Targets cancer immunotherapy necessitates the applica- 3: Implications for TIM-3 Blockade in Cancer Faculty beyond CTLA-4/PD-1 Axes tion of cellular models closely resembling patient Pushpa Jayaraman, Ph.D., Investigator II, Catherine Sabatos-Peyton, Ph.D., Senior Investigator, tumors. In my talk, I will present data derived from a Exploratory Immuno-Oncology, Novartis Novartis Institutes for BioMedical Research patient-derived model system involving the co-culture Institutes for BioMedical Research of 3D tumor spheroids and T lymphocytes. Imag- With the proven clinical efficacy of PD-1/PD-L1 Short Courses TIM-3, a T cell exhaustion marker, is more dominant ing-based analyses of these models allow for the and CTLA-4 agents in multiple cancer indications, on myeloid cells than on T cells in murine syngene- evaluation of T lymphocyte infiltration as well as T immunotherapy has come to the forefront as a way ic tumor models and in renal cell carcinoma (RCC) cell induced cytotoxicity in the spheroids in response to modulate an anti-tumor response. Beyond the treatment-naive patients. We present data that TIM- to antigen stimulation and/or compound treatment. PD-1/PD-L1 axis, multiple other checkpoint inhibi- Sponsor & Exhibit 3+ myeloid cells are dysfunctional, and that TIM-3 tors, including LAG-3 and TIM-3, have moved into the blockade rescues myeloid pro-inflammatory function. Opportunities 11:45 Tipping the Balance: Overriding clinic and distinct modalities may lead to synergistic The pathophysiological role of the TIM-3 pathway in anti-tumor effects with PD-1 pathway co-blockade. Phosphatidylserine-Mediated Tumor innate immunity might have important consequences Coordinated modulation of the tumor microenvi- Immune Suppression to Enhance on T cell function and TIM-3 blockade in cancer. Training Seminar Immune Checkpoint Therapies ronment by relieving suppressive pathways to favor 2:30 New Targets for Human CD8+ effector T cell activation may open avenues to Bruce Freimark, Ph.D., Research Director, broader applicability of immunotherapy in cancer. Preclinical Oncology, Peregrine Pharmaceuticals Cancer Immunotherapy Agenda Phosphatidylserine (PS) exposure in tumors in- Xingxing Zang, Ph.D., Associate Professor, 4:45 Of Mice and Men: Translating the Immune duces non-inflammatory signals which contribute Microbiology and Immunology & Medicine, Oncology Mechanism of Action of NKTR-214 to an immunosuppressive environment. Antibody Albert Einstein College of Medicine Jonathan Zalevsky, Ph.D., Vice President, Biology blockade of PS activates immune responses by CTLA-4 and the PD-1/PD-L1 pathway are current & Preclinical Development, Nektar Therapeutics promoting M1 macrophages, maturation of dendrit- Hotel & Travel focuses for cancer immunotherapy. This presen- NKTR-214, a CD122-biased immune-stimulatory ic cells and inducing adaptive T-cell responses. PS tation will discuss other new immune checkpoints cytokine, is designed to expand the numbers and Information targeting antibodies enhance the anti-tumor activity for future human cancer immunotherapy. activity of tumor-killing lymphocytes and has shown and survival of checkpoint antibodies in preclinical promising preclinical results as a single agent and tumor models by increasing activated cytotoxic T-cell 3:00 Modulating Interferon-Gamma Induced in combination with checkpoint inhibitors, cell-ther- infiltrates and immune stimulatory mediators. Registration PD-L1 Expression in Medulloblastoma apies, and vaccines. In the Phase I/II clinical study, Information 12:15 pm Enjoy Lunch on Your Own Alex Yee-Chen Huang, M.D., Ph.D., translational research will assess the immunologic Associate Professor, Pediatrics, Pathology effect of NKTR-214 on tumor-infiltrating lymphocytes & Biomedical Engineering, Case Western (TILs) and other immune cells in both blood and serial Reserve University School of Medicine tumor biopsies to identify potential biomarkers. Click Here to Tumors up-regulate immune checkpoint molecules, including PD-L1, in response to immune effector 5:15 Discussion with Session Speakers Register Online! cytokines such as interferon-gamma. Recent data Immuno-Oncology have revealed new molecular target(s), the interfer- 5:45 Close of Preclinical and Translational Summit.com ence of which can modulate PD-L1 expression by Immuno-Oncology Conference

250 First Avenue Needham, MA 02494 www.healthtech.com THU-FRI | SEPTEMBER 1-2 Cover Adoptive T Cell Therapy Conference- Delivering CAR, TCR, and TIL from Research to Reality at-a-Glance

Keynotes THURSDAY, SEPTEMBER 1 9:30 Development of an Anti-BCMA Specific lymphomas, we also implemented a Phase I study with CAR with Potent Anti-Multiple Myeloma Activity CAR-T cells targeting the CD30 antigen. Outcome of these studies and future directions will be reported. 7:45 am Registration & Morning Coffee Richard A. Morgan, Vice President, Faculty Immunotherapy, bluebird bio 11:45 PANEL: CAR T Cell Therapy: Target PRINCIPALS OF ENGINEERED B cell maturation antigen (BCMA) is expressed on Antigen Discovery and Clinical Translation most multiple myeloma (MM) cells, yet normal tissue RECEPTOR DESIGN Panelists: Adrian Bot, M.D., Ph.D., Vice President, expression is limited to plasma and some B cells. Translational Sciences, R&D, Kite Pharma Inc. Short Courses 8:25 Chairperson’s Opening Remarks Here we demonstrate that a potent, antigen-de- pendent, memory-like BCMA CAR T cells can be Gianpietro Dotti, M.D., Professor, Microbiology Adrian Bot, M.D., Ph.D., Vice President, produced with a scalable manufacturing process and Immunology, University of North Carolina Translational Sciences, R&D, Kite Pharma Inc. that mediated robust tumor regressions in animal Richard A. Morgan, Vice President, Sponsor & Exhibit models. A Phase I clinical trial to test this approach Immunotherapy, bluebird bio in patients with relapse refractor MM is underway. • Market potential of anti-CD19 CAR T Cells Opportunities 8:30 KEYNOTE PRESENTATION: 10:00 Coffee Break with Exhibit • The latest clinical results NEW APPROACHES TO OVERCOME • Scalability and manufacturing challenges and Poster Viewing TUMOR IMMUNE SUPPRESSION • Future directions for CAR therapies Training Seminar FOR T-CELL THERAPY Laszlo Radvanyi, Ph.D., Senior Vice President TARGETS FOR T CELL INTERVENTIONS 12:15 pm Sponsored Presentations and Head, Immuno-Oncology Translational (Opportunities Available) Innovation Platform (TIP), EMD Serono 10:45 CD19 as a Prototypic B Cell Agenda Adoptive T-cell transfer therapies have made Lineage Target for CAR T Cells 12:45 Luncheon Presentation tremendous progress for treating cancer, with Adrian Bot, M.D., Ph.D., Vice President, (Sponsorship Opportunity Available) successes emerging especially in hematologic Translational Sciences, R&D, Kite Pharma Inc. or Enjoy Lunch on Your Own Hotel & Travel malignancies. Although, these cell therapies Anti-CD19 CAR T cells could be the first marketed offer new ways of genetically reprogramming T products in this space. Prolonged B cell deficiency 1:15 Session Break Information cells through altered specificities and redirecting may not be desirable since B cells are required to com- T-cell signaling pathways, immune suppressive bat major pathogens. Product candidates capable to 2:00 Chairperson’s Remarks mechanisms in the tumor microenvironment, mediate rapid and profound tumor debulking, can yield Adrian Bot, M.D., Ph.D., Vice President, durable clinical responses without persisting B cell such as PD-1-PD-L1 axis, TGF-beta, and an Translational Sciences, R&D, Kite Pharma Inc. Registration deficiency. Novel evidence will be presented, linking Information insufficient Th1 response, still raise great challenges to success in solid tumors. Some key product characteristics, conditioning, and biomark- 2:05 Human Papillomavirus (HPV)-Targeted ers, to the clinical outcome afforded by CAR T cells. agents aimed at overcoming these issues being T Cells for HPV-Associated Cancers developed at EMD Serono will be presented. 11:15 CAR-T Cells for Hematological Christian S. Hinrichs, M.D., Investigator, Click Here to Malignancies: Exploring Alternative Targets Experimental Transplantation and Immunology Branch, Lasker Clinical Research Scholar, NIH Register Online! 9:00 Engineering Better T Cells Gianpietro Dotti, M.D., Professor, Microbiology Immuno-Oncology and Immunology, University of North Carolina Human papillomavirus (HPV) causes cancers of Daniel Williams, Head, UK Research the uterine cervix, oropharynx, anus, vulva, vagi- Summit.com Operations, Adaptimmune Adoptive transfer of CD19-specific CAR-T cells showed remarkable anti-tumor activity in patients with B-cell na and penis. These cancers express the HPV E6 Adaptimmune is a clinical-stage biopharmaceutical derived acute lymphoblastic leukemia and lympho- and E7 oncoproteins, which are attractive immu- company developing engineered TCRs for adoptive mas. Alternative targets have been explored in Phase notherapeutic targets. Recent work has sought T cell therapy. Engineering TCRs specific for tumor I studies in hematological malignancies. Specifically, to target these antigens using tumor-infiltrating antigens which are self-antigens, requires balancing in the effort to reduce the B cell aplasia associated lymphocytes and genetically engineered T cells. the need for increasing affinity to the target peptide with effective and long-term persisting CD19-specific to allow recognition of immune-selected tumors, CAR T cells, we implemented at Baylor College of 2:35 XPRESIDENT®-Guided Target with the risk of cross-reactivity, which increases at Medicine a Phase I study with CAR-T cells targeting the Identification and Profiling of On-and Off- higher affinities. Target identification and validation, k-light chain of human immunoglobulin to selectively Target Toxicity for Safer Adoptive Cell Therapy together with a broad and robust preclinical safety 250 First Avenue eliminate k+ tumors whilst sparing normal l+ B lympho- testing strategy are critical in the development of Steffen Walter, Ph.D., CSO, Immatics Needham, MA 02494 cytes. To target Hodgkin’s Lymphoma and other CD30+ www.healthtech.com safe and efficacious affinity-enhanced TCRs. Biotechnologies GmbH Cover A major constraint for the broad and safe appli- Biology and Gene Therapy, Humboldt University Berlin CAR T-cell therapy for solid tumors is prone to the cation of Adoptive Cellular Therapy is the limited David M. Kranz, Phillip A. Sharp Professor, checkpoint blockade inhibition similar to innate number of validated tumor targets and TCRs. We Biochemistry, Biochemistry, University of Illinois tumor-infiltrating lymphocytes. Strategies to over- used a proprietary target discovery engine (XPRESI- come this ‘Adaptive Resistance’ of infused CAR • Strategies for antigen selection and targeting Conference- DENT®) combining highly sensitive quantitative mass T cells can promote their anti-tumor efficacy and • Increasing sensitivity and specificities at-a-Glance spectrometry, transcriptomics, immunology and functional persistence. Understanding solid tumor bioinformatics to characterize the immunopeptidome • Utilizing efficient gene delivery systems type-specific immune microenvironment can guide directly on human normal and tumor tissues. We show • Dealing with toxicities both cell-intrinsic and extrinsic strategies that how this approach can be used to predict on- and can modulate the solid tumor microenvironment Keynotes off-target toxicities in TCR-based immunotherapies. 5:05 End of Day in addition to promoting CAR T-cell efficiency. 3:05 Engineering Designer T 10:00 Coffee Break FRIDAY, SEPTEMBER 2 Faculty Cells for Immunotherapy Wolfgang Uckert, Associate Professor, MANUFACTURE AND SCALE-UP 8:00 am Morning Coffee Department of Cell Biology and Gene Therapy, Humboldt University Berlin 10:30 Challenges and Opportunities for Scale-up of CAR T Cells Short Courses Successful immunotherapy using T cell receptor TARGETING SOLID TUMORS (TCR) gene-modified T cells to treat cancer, viral Máire Quigley,Ph.D., Research Investigator I, infections or autoimmune diseases is depending on 8:25 Chairperson’s Opening Remarks Cell and Gene Therapies Unit, Novartis the careful selection of: (i) the target antigen, (ii) a Jonathan Gilbert, Director, Strategic The response rates of autologous CAR T cell ther- Sponsor & Exhibit TCR with optimal affinity, (iii) an efficient gene delivery Scientific Partnerships, SQZ Biotech apies in early clinical trials give hope that these Opportunities system, and (iv) a safety switch to interrupt therapy treatments can be developed and widely distrib- in case of severe adverse side effects. Examples of 8:30 Vector-Free Engineering of Immune uted to patients with unmet need. To successfully these different areas to generate designer T cells for Cells for Enhanced Antigen Presentation evolve from small scale production to commercial successful TCR gene therapy are given and discussed. Jonathan Gilbert, Director, Strategic manufacturing, multiple challenges must be over- Training Seminar Scientific Partnerships, SQZ Biotech come. Lessons learned from the process scale up 3:35 Refreshment Break of CD19 CAR T cell production will be discussed. Robust engineering of immune cell function is critical to realizing the therapeutic potential of cell 11:00 Cell Therapy: Quality and therapies in cancer. Our vector-free CellSqueeze Good Manufacturing Practices Agenda 4:05 KEYNOTE PRESENTATION: A technology has demonstrated novel capabilities in COMPARISON OF TCRS AND CARS: diverse areas including engineering antigen pre- Yeong “Christopher” Choi, Ph.D., Director, TCPF SENSITIVITIES AND SPECIFICITIES sentation to drive powerful and significant T-cell and Assistant Professor, Oncology, Center for Hotel & Travel David M. Kranz, Phillip A. Sharp responses. We will present recent developments Immunotherapy, Roswell Park Cancer Institute Professor, Biochemistry, University in our cell-based immunotherapy programs aimed To bring ground breaking new cell therapies into the Information of Illinois, Urbana-Champaign at using patient-derived antigens to target a variety clinic, a massive amount of infrastructure is needed. T cells, via their T-cell receptors (TCRs), evolved of cancer indications, including solid tumors. One of the key components is a drug manufactur- to target intracellular peptides as low-density, ing facility, which is compliant with US FDA GMP 9:00 Design of a Highly Efficacious CAR Registration cell-surface complexes with MHC products. regulations. One of the major challenges of oper- Synthetic constructs known as chimeric antigen Targeting Mesothelin in Solid Tumors ating a cell therapy cGMP facility, is maintaining a robust Quality Management System. Fortunately, Information receptors (CARs) contain an anti-tumor antigen Boris Engels, Ph.D., Investigator, Exploratory Immuno- there are a number of voluntary accrediting organi- scFv and recognize higher density antigens. Oncology, Novartis Institutes for Biomedical Research zations to promote excellence in the laboratory. We have designed high-affinity human TCRs in The treatment of solid tumors with CAR T cells re- conventional heterodimer format and in CAR-like mains challenging. We describe the design of a human 11:30 Manufacturing of Cellectis’ Click Here to CAR targeting mesothelin, a tumor associated antigen formats to directly compare features of both Allogeneic UCART Product Candidates Register Online! systems. These features include T cell surface overexpressed in many cancers. A pooled screen iden- Arjan Roozen, Vice President, GMP Immuno-Oncology levels, antigen sensitivities and other properties. tified scFvs, which show enhanced efficacy, superior Solutions & Manufacturing, Cellectis Summit.com to the CARs currently used in the clinic. We performed in-depth characterization of the scFvs and CARs This talk will provide an introduction of the concept to gain insight into structure-activity relationships, of Cellectis’ allogeneic UCART product candidates 4:35 PANEL: Designing T Cells which may influence CAR efficacy and future design and our technological platform. It will describe and for Immunotherapies explain the challenges during the process of bring- Panelists: 9:30 Overcoming CAR T Cell Checkpoint ing allogeneic UCART product candidates from Christian S. Hinrichs, M.D., Investigator, Blockade in Solid Tumors R&D development phase to the GMP manufacturing Experimental Transplantation and Immunology Prasad S. Adusumilli, M.D., FACS, FCCP, Deputy phase, in order to have CTM (clinical trial material) Branch, Lasker Clinical Research Scholar, NIH Chief, Translational and Clinical Research, available for clinical studies, and afterwards to plan Steffen Walter, Ph.D., CSO, Immatics Thoracic Surgery; Associate Attending, Thoracic commercial manufacturing of Cellectis’ allogene- 250 First Avenue Surgery; Member, Center for Cell Engineering, ic UCART GMP cellular gene therapy products. Needham, MA 02494 Biotechnologies GmbH www.healthtech.com Wolfgang Uckert, Ph.D., Associate Professor, Cell Memorial Sloan-Kettering Cancer Center 12:00 pm Close of Adoptive T Cell Therapy THU-FRI | SEPTEMBER 1-2 Cover Biomarkers for Immuno-Oncology Conference- Predictive Biomarkers and Companion Diagnostics to Guide Cancer Immunotherapy at-a-Glance

Keynotes THURSDAY, SEPTEMBER 1 BIOMARKERS TO GUIDE 12:15 pm Multiscalar Systems Sponsored by: IMMUNOTHERAPY Modeling to Design Rational 7:45 am Registration & Morning Coffee Cancer Immunotherapy 10:45 Regulatory Considerations for Combinations Faculty COMPANION DIAGNOSTICS Diagnostics to Guide Cancer Immunotherapy Spyro Mousses, Ph.D., President, FOR IMMUNOTHERAPY Janaki Veeraraghavan, Ph.D., Biologist, Office Systems Imagination, Inc. of In Vitro Diagnostics and Radiological Health, This case study will describe the mining and mod- Center for Devices and Radiological Health, FDA Short Courses 8:25 Chairperson’s Opening Remarks eling of disparate types of information ranging Kenneth Emancipator, M.D., Executive Medical from WGS data to deep clinical phenotype data 11:15 Novel T Cell Biomarkers for Response Director, Companion Diagnostics, Merck & Co. including pathological and radiological images. to PD-1 and PD-1/CTLA4 Immunotherapy Results identified hidden insights that can be lev- Sponsor & Exhibit 8:30 Developing an Immunohistochemistry Test Adil Daud, M.D., Professor, Hematology/Oncology, eraged to design safer and more effective drug Opportunities for Programmed Cell Death Ligand 1 (PD-L1) as University of California, San Francisco; Director, combinations for cancer immunotherapy. a Companion Diagnostic for Pembrolizumab Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center 12:30 Sponsored Presentation Kenneth Emancipator, M.D., Executive Medical Immunotherapy with checkpoint inhibitors has (Opportunity Available) Director, Companion Diagnostics, Merck & Co. Training Seminar revolutionized the treatment of many cancers. Tumors express PD-L1 to contribute to escape from However, even with these agents, 40-60% of patients 12:45 Luncheon Presentation: Sponsored by: immunosurveillance. Pembrolizumab blocks this es- with advanced melanoma, 50-80% of patients with Precision Proteomics— cape mechanism and thus effectively treats a number NSCLC, and even higher proportions of patients in Enabling Solutions for the Field Agenda of cancers. The rapid clinical development of pem- other cancers do not respond. While earlier studies of Immuno-Oncology brolizumab required rapid development of an immu- had examined PDL-1 as a marker for response, a Ida Grundberg, Ph.D., Olink Proteomics nohistochemistry assay for PD-L1. Merck developed deeper understanding is now emerging integrating Seunghee Kim-Schulze, Assistant Professor of the assay initially to determine whether or not PD-L1 several tumor and host factors; these include tumor Hotel & Travel is a predictive biomarker, then to enrich clinical trials, neo-antigens and mutational burden, T cell and Medicine, Hess Center for Science and Medicine, Information and ultimately partnered with a diagnostics company APC activation as well as host factors such as the Human Immune Monitoring Core Facility to develop the assay as a companion diagnostic. presence or absence of certain metastatic locations (HIMC), Mount Sinai School of Medicine which can determine success with immunotherapy. Proseek® panels from Olink Proteomics are power- 9:00 Diagnostic Strategies for Cancer ful tools for targeted protein biomarker discovery. Registration Immune Therapy Combinations 11:45 Immuno-Oncological Biomarkers A new panel of 92 protein biomarkers focusing Information Andy Williams, Ph.D., Companion Diagnostics Group in Hematological and Solid Tumors on immuno-oncology is designed to facilitate a Leader, Cancer Immune Therapies, Genentech Scott Rodig, M.D., Ph.D., Associate Professor, better understanding of the interplay between the Current and future diagnostic opportunities for cancer Pathology, Harvard Medical School; Associate immune system and tumors, evaluate therapeu- tic efficacy and provide the foundation for patient immune therapies will be covered. This will include Pathologist, Pathology, Brigham & Women’s Hospital companion diagnostics and other informative tests. stratification. Our innovative Proximity Extension Click Here to Clinical response to immune checkpoint inhibitors Assay (PEA) technology enables high-multiplex Register Online! 9:30 Integration of Cancer Immunotherapy is associated, in part, to tumor-specific expression immunoassays without comprising data quality. A of the PD-1 ligands (PDLs) PD-L1 and PD-L2. PDLs recent customer case study will be presented. Immuno-Oncology into Precision Medicine are upregulated on tumor cells by cell autonomous Summit.com Zhen Su, M.D., MBA, Senior Vice President, Global and microenvironmental mechanisms. I will speak 1:15 Session Break Head of Medical Affairs Oncology, EMD Serono about a genetic basis for PD-L1 and PD-L2 expression found in a subset of hematological malignancies and 10:00 Coffee Break with Exhibit a subset of solid tumors. The correlations between BIOMARKER DEVELOPMENT FOR and Poster Viewing genetics, tumor phenotype, and patient response to PERSONALIZED IMMUNOTHERAPY chemotherapy and immune therapy will be discussed. 2:00 Chairperson’s Remarks Chan Whiting, Ph.D., Director, Immune Monitoring/ Biomarker Development, Aduro Biotech 250 First Avenue Needham, MA 02494 www.healthtech.com Cover 2:05 Emerging Biomarkers and Novel 4:35 NanoFACS: Extracellular Vesicle Subset 9:30 Checkpoint Inhibitors in Combination: High-Throughput Technologies for Sorting and Analysis for Personalized Medicine Novartis Enters the Clinic Personalized Cancer Immunotherapy Jennifer C. Jones, M.D., Ph.D., Assistant Clinical Jennifer Mataraza, Ph.D., Senior Investigator, Immune Conference- Jianda Yuan, M.D., Ph.D., Director, Translational Investigator, Molecular Immunogenetics & Vaccine Oncology, Novartis Institutes for BioMedical Research at-a-Glance Immuno-Oncology Research, Merck Research Labs Research Section, Vaccine Branch, National This presentation will cover: (1) the role of checkpoint There is a growing need to identify predictive and prog- Cancer Institute, National Institutes of Health inhibitors in the context of a broader immu- nostic biomarkers that enhance our understanding of no-oncology strategy; (2) an outline of the sta- the mechanisms underlying the complex interactions 5:05 Biomarkers for Cancer Immunotherapy tus of the Novartis checkpoint pipeline; Keynotes between the immune system and cancer. We (SITC Using Live-Attenuated Listeria monocytogenes (3) approaches to the discovery of nov- Biomarker Task Force Working Group 2 with interna- Chan Whiting, Ph.D., Director, Immune Monitoring/ el CPIs and overcoming resistance. tional experts from academia and industry) assemble Biomarker Development, Aduro Biotech 10:00 Coffee Break to identify and discuss promising technologies for bio- A live-attenuated double deleted Lm (LADD) im- Faculty marker discovery and validation. We review the current munotherapy induces systemic cytokines, repro- 10:30 Novel Approaches for Combination status of emerging biomarkers for immune checkpoint grams the tumor microenvironment and provides blockade therapy and discuss novel technologies clinical benefit. A description of Listeria-based Immunotherapy of Cancer: Lessons Short Courses as well as high dimensional data analysis platforms immunotherapy of clinical studies in mesothelio- Learned and Future Opportunities that will be pivotal for future biomarker research. ma, pancreatic cancers including comprehensive Jon Wigginton, M.D., CMO & Senior Vice 2:35 High-Dimensional Single Cell immune monitoring and biomarker development President, Clinical Development, MacroGenics efforts in these settings will be discussed. Analyses in Tumor Tissues There has been tremendous progress in the field of Sponsor & Exhibit cancer immunotherapy as it has moved recently into Opportunities Sacha Gnjatic, Ph.D., Associate Professor, Tisch 5:35 End of Day the mainstream for the treatment of many cancers. A Cancer Institute, Hematology/Oncology, Immunology, broad range of non-clinical studies, and more recently, Icahn School of Medicine at Mount Sinai FRIDAY, SEPTEMBER 2 powerful new clinical data from studies combining The density and distribution of immune cells at the anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) Training Seminar tumor site can be useful as a prognostic or predic- for the treatment of patients with melanoma, have tive marker of clinical response in many different 8:00 am Morning Coffee focused considerable attention on the potential cancers. New high-dimensional analysis tools for promise of combination cancer immunotherapy. both fresh and preserved tissues are now available to CLINICAL IMMUNO-ONCOLOGY This presentation will provide an overview of current Agenda assess the phenotypic and functional tumor immune COMBINATIONS progress, lessons learned, and future prospects microenvironment with unprecedented depth and for the combination immunotherapy of cancer. complexity. These studies are poised to help better 8:25 Chairperson’s Opening Remarks define local immunocompetence in individual patients, 11:00 Combined Il-15-Based Cytokine Therapy Jan ter Meulen, M.D., Dr.habil., Hotel & Travel and correlate it with peripheral immune markers DTM&H, CSO, Immune Design with PD-1 Immune Checkpoint Blockade in Information and predicted outcome, to improve patient stratifi- Advanced Non-Small Cell Lung Cancer cation to immunotherapies or other interventions. 8:30 Clinical Immuno-Oncology Combinations John Wrangle, M.D., Assistant Professor, 3:05 B Cell-Related Biomarkers in Cancer Kevin Horgan, Ph.D., Vice President, Immuno- Medicine, Hematology/Oncology, Medical Registration Sam Hanash, M.D., Ph.D., McCombs Institute for Oncology Global Medicines Development, AstraZeneca University of South Carolina the Early Detection and Treatment of Cancer Information 9:00 Cancer Immunotherapy and Biomarker 11:30 Inducing Local and Systemic 3:35 Refreshment Break Strategies for Combination Studies Anti-Tumor Responses through in situ Jeffrey Wallin, Ph.D., Group Leader, Early Stage Vaccination: Synergy of the TLR4 Agonist Click Here to 4:05 Human Tissue as a Platform for Oncology Biomarker Development, Genentech G100 with Localized Radiation Therapy Developing Predictive Biomarkers: The activation of anti-tumor immunity by immune Jan ter Meulen, M.D., Dr.habil., Register Online! A Case Study in PD-L1 checkpoint blockade has demonstrated efficacy in DTM&H, CSO, Immune Design Immuno-Oncology Robert Anders, M.D., Ph.D., Associate Professor, a variety of cancers. Although durable responses The immunosuppressive tumor microenvironment Summit.com Pathology, Johns Hopkins University have been observed, combination approaches will (TME) is a main obstacle to successful cancer be required to extend this benefit beyond a subset Pathologic examination of human tissue has long immunotherapy. Intratumoral injection of the TLR4 of patients. Combinations for cancer immuno- served as a prognostic biomarker. Increasingly, human agonist Glucopyranosyl Lipid A in stable emulsion therapy involve promotion of one or more steps tissue is being used to develop predictive biomarkers (G100) induces in a pro-inflammatory state of the TME of the cancer-immunity cycle and biomarkers can in the form of immunohistochemistry-based compan- that promotes local and systemic immune responses provide valuable diagnostic and mechanistic infor- ion or complementary diagnostic tests. However, the and tumor control via CD8 T cells. Focal irradiation of mation for cancer immunotherapy clinical trials. evaluation of immunohistochemical studies must be tumors enhances G100-mediated tumor control, espe- considered in the context of i) tumor type, ii) immune cially of non-treated lesions (abscopal effect), and sup- microenvironment, iii) relationship to treatment, and ports clinical development as a combination therapy. 250 First Avenue iv) limitations of immunohistochemical staining. Needham, MA 02494 12:00 pm Close of Biomarkers for www.healthtech.com Immuno-Oncology Conference THU-FRI | SEPTEMBER 1-2 Cover Clinical Trials for Cancer Immunotherapy Conference- Strategies to Accelerate Immuno-Oncology Clinical Development at-a-Glance

shown robust antitumor activity against several Keynotes THURSDAY, SEPTEMBER 1 IMMUNO-ONCOLOGY CLINICAL DEVELOPMENT STRATEGIES advanced malignancies. The safety and efficacy 7:45 am Registration & Morning Coffee of pembrolizumab in patients with PD-L1-posi- 10:45 PD-1 Antibody Has the Potential to Be tive advanced breast cancer (triple-negative and ER-positive/HER2-negative) will be discussed. Faculty COMPANION DIAGNOSTICS a Broad Spectrum Antineoplastic Therapy FOR IMMUNOTHERAPY Roy D. Baynes, M.D., Ph.D., Senior Vice 2:35 The Role of Immune-Checkpoint Therapy President and Head, Global Clinical in Cancers with Deficient Mismatch Repair Development, Merck Research Laboratories Short Courses 8:25 Chairperson’s Opening Remarks Michael J. Overman, M.D., Associate Professor, PD-1 antibody blocks ligands PDL-1 and PDL-2 binding Kenneth Emancipator, M.D., Executive Medical Gastrointestinal Medical Oncology, University to PD-1 receptor, and activates cytotoxic killer cells, Director, Companion Diagnostics, Merck & Co. of Texas MD Anderson Cancer Center revealing innate immunity to cancer. Big data sets evaluating PDL-1 expression and mutational burden Initial investigations of immune-checkpoint ther- Sponsor & Exhibit 8:30 Developing an Immunohistochemistry Test apy targeting PD1/PDL1 in unselected colorectal Opportunities for Programmed Cell Death Ligand 1 (PD-L1) as were interrogated to accelerate development. This enabled early approvals in malignant melanoma and cancer (CRC) have demonstrated limited to no a Companion Diagnostic for Pembrolizumab NSCLC along with a companion diagnostic. More than activity. However, a subset of CRC, characterized Kenneth Emancipator, M.D., Executive Medical 20 different responsive cancers have been identified. by mismatch deficiency or microsatellite instability Training Seminar Director, Companion Diagnostics, Merck & Co. Precision medicine approaches identify patients for (MSI-high), has demonstrated robust early signals Tumors express PD-L1 to contribute to escape from whom monotherapy is most appropriate and those of anti-tumor activity with PD1 targeting. It is now immunosurveillance. Pembrolizumab blocks this es- for whom additional therapies should be considered. clear that MSI-high cancers represent a unique cape mechanism and thus effectively treats a number molecular and immunological tumor subset. This talk Agenda of cancers. The rapid clinical development of pem- 11:15 The Combination Conundrum will discuss the current and ongoing clinical trials brolizumab required rapid development of an immuno- James E. Wooldridge, M.D., CSO, Immuno-Oncology investigating immune therapy in this disease subset. histochemistry assay for PD-L1. Merck developed the Clinical Development, Eli Lilly and Company 3:05 Attend concurrent session assay initially to determine whether or not PD-L1 is Hotel & Travel a predictive biomarker, then to enrich clinical trials, 11:45 Cancer Immunotherapy: 3:35 Refreshment Break Information and ultimately partnered with a diagnostics company Triumphs and Challenges to develop the assay as a companion diagnostic. Joseph Pearlberg, M.D., Ph.D., Senior Medical 4:05 Checkpoint Inhibitors for Gliomas 9:00 Diagnostic Strategies for Cancer Director, Infinity Pharmaceuticals Michael Lim, M.D., Associate Professor, Registration Immune Therapy Combinations Neurosurgery, Oncology and Radiation Oncology, 12:15 pm Enjoy Lunch on Your Own Johns Hopkins University School of Medicine Information Andy Williams, Ph.D., Companion Diagnostics Group Leader, Cancer Immune Therapies, Genentech The poor prognosis of patients with glioblastoma CLINICAL DEVELOPMENT FOR mandates new approaches. Checkpoint inhibitors Current and future diagnostic opportunities for cancer CHECKPOINT INHIBITORS are an exciting class of immune-based strategies immune therapies will be covered. This will include Click Here to that have been shown to improve survival in solid companion diagnostics and other informative tests. 2:00 Chairperson’s Remarks Register Online! tumors such as melanoma, lung cancers, and renal 9:30 Integration of Cancer Immunotherapy Vassiliki Karantza, M.D., Ph.D., Director, Clinical cell cancers. We will discuss the state of check- Immuno-Oncology into Precision Medicine Research Oncology, Merck Research Laboratories point inhibitors in glioblastoma. We will specifical- Summit.com ly focus on the existing preclinical data, current Zhen Su, M.D., MBA, Senior Vice President, Global 2:05 PD-1 Inhibition by Pembrolizumab clinical trials, and future combination approaches Head of Medical Affairs Oncology, EMD Serono for Breast Cancer Treatment with checkpoint inhibitors for glioblastoma. 10:00 Coffee Break with Exhibit Vassiliki Karantza, M.D., Ph.D., Senior Director, Clinical 4:35 Clinical Biomarkers of a STAT3 Research Oncology, Merck Research Laboratories and Poster Viewing Antisense Oligonucleotide, AZD9150 The PD-1 receptor-ligand pathway is used by tumors Patricia McCoon, Ph.D., Principal Scientist, to evade immune surveillance. Pembrolizumab is Oncology IMED Translational Science, a humanized anti–PD-1 monoclonal antibody that AstraZeneca Pharmaceuticals blocks the interaction between PD-1 and its ligands, 250 First Avenue AZD9150 is a therapeutic antisense oligonucle- Needham, MA 02494 PD-L1 and PD-L2, thus reactivating the immune www.healthtech.com system to eradicate tumors. Pembrolizumab has otide targeting STAT3 that has shown clinical Cover safety and efficacy in two Phase I clinical trials. a variety of cancers. Although durable responses progress, lessons learned, and future prospects Clinical biomarker analysis demonstrated STAT3 have been observed, combination approaches will for the combination immunotherapy of cancer. knockdown in immune cells, and additional gene be required to extend this benefit beyond a subset Conference- expression changes associated with better re- of patients. Combinations for cancer immunother- 11:00 Combined Il-15 Based Cytokine Therapy sponse to immune checkpoint blockade. Addition of apy involve promotion of one or more steps of the with PD-1 Immune Checkpoint Blockade in at-a-Glance mouse STAT3 ASO to anti-PDL1 treatment showed cancer-immunity cycle and biomarkers can provide Advanced Non-Small Cell Lung Cancer benefit in preclinical syngeneic tumor models. valuable diagnostic and mechanistic informa- John Wrangle, M.D., Assistant Professor, Based on these data, Phase Ib/2 clinical trials have tion for cancer immunotherapy clinical trials. Medicine, Hematology/Oncology, Medical been initiated testing AZD9150 + durvalumab. University of South Carolina Keynotes 9:30 Cancer Immunotherapy in Combination 5:05 Attend Concurrent Session Jennifer Mataraza, Ph.D., Senior Investigator, Immune 11:30 Inducing Local and Systemic Oncology, Novartis Institutes for BioMedical Research Anti-Tumor Responses through in situ 5:35 End of Day Faculty This presentation will cover: (1) the role of checkpoint Vaccination: Synergy of the TLR4 Agonist inhibitors in the context of a broader immuno-on- G100 with Localized Radiation Therapy cology strategy; (2) an outline of the status of the FRIDAY, SEPTEMBER 2 Jan ter Meulen, M.D., Dr.habil., Novartis checkpoint pipeline; (3) approaches to the DTM&H, CSO, Immune Design Short Courses discovery of novel CPIs and overcoming resistance. 8:00 am Morning Coffee The immunosuppressive tumor microenviron- 10:00 Coffee Break ment (TME) is a main obstacle to successful CLINICAL IMMUNO-ONCOLOGY cancer immunotherapy. Intratumoral injection of Sponsor & Exhibit COMBINATIONS 10:30 Novel Approaches for Combination the TLR4 agonist Glucopyranosyl Lipid A in stable Opportunities Immunotherapy of Cancer: Lessons emulsion (G100) induces in a pro-inflammatory 8:25 Chairperson’s Opening Remarks Learned and Future Opportunities state of the TME that promotes local and sys- Jan ter Meulen, M.D., Dr.habil., Jon Wigginton, M.D., CMO & Senior Vice temic immune responses and tumor control via DTM&H, CSO, Immune Design President, Clinical Development, MacroGenics CD8 T cells. Focal irradiation of tumors enhanc- Training Seminar es G100-mediated tumor control, especially of There has been tremendous progress in the field of 8:30 Clinical Immuno-Oncology Combinations non-treated lesions (abscopal effect), and supports cancer immunotherapy as it has moved recently into clinical development as a combination therapy. Kevin Horgan, Ph.D., Vice President, Immuno- the mainstream for the treatment of many cancers. A Oncology Global Medicines Development, AstraZeneca Agenda broad range of non-clinical studies, and more recently, 12:00 pm Close of Clinical Trials for powerful new clinical data from studies combining 9:00 Cancer Immunotherapy and Biomarker Cancer Immunotherapy Conference anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) Strategies for Combination Studies Hotel & Travel for the treatment of patients with melanoma, have Jeffrey Wallin, Ph.D., Group Leader, Early Stage focused considerable attention on the potential Information Oncology Biomarker Development, Genentech promise of combination cancer immunotherapy. The activation of anti-tumor immunity by immune This presentation will provide an overview of current checkpoint blockade has demonstrated efficacy in Registration Information

Click Here to Register Online! Immuno-Oncology Summit.com

250 First Avenue Needham, MA 02494 www.healthtech.com Cover

Conference- at-a-Glance Conference Venue and Hotel:

Keynotes Marriott Long Wharf 296 State Street Faculty Boston, MA 02109 T: 617.227.0800 Short Courses Reservations: Go to the travel page of Sponsor & Exhibit Immuno-OncologySummit.com. Opportunities Discounted Room Rate: $289 s/d Training Seminar Discount Cut-off Date: August 1, 2016 Agenda

Hotel & Travel Information

Registration Information

Click Here to Register Online! Immuno-Oncology Summit.com

250 First Avenue Needham, MA 02494 www.healthtech.com Cover IO Immuno-Oncology SUMMIT 2016 Complimentary news delivered to your inbox Conference- at-a-Glance SHORT COURSES News on the data deluge in petascale computing and the tools to deliver Academic, Government, individualized medicine. Commercial Hospital-affiliated Bio-ITWorld.com Keynotes One short course $699 $399 Two short courses $999 $699 Insights on the innovation between Tuesday, August 30, 6:30-9:00 clinical trial management and delivery of care. ClinicalInformaticsNews.com Faculty SC1: Targeting the Cancer Mutanome SC2: Bispecific Antibody Development for Immunotherapy Emerging Technologies in Diagnostics Short Courses CONFERENCE AND TRAINING SEMINAR PACKAGES DiagnosticsWorldNews.com PREMIUM PACKAGE (Includes access to all conferences and Training Seminar Monday – Friday. Excludes short courses.) Early Registration until June 10 $2,949 $1,499 Sponsor & Exhibit Advance Registration until July 29 $3,099 $1,699 Reports designed to keep life science Opportunities Registration after July 29 $3,299 $1,799 professionals informed of the salient trends in pharma technology, business, STANDARD PACKAGE (Includes access to 2 conferences and/or Training Seminar. Excludes short courses.) clinical development, and therapeutic disease markets Early Registration until June 10 $2,499 $1,229 InsightPharmaReports.com Training Seminar Contact Adriana Randall, Advance Registration until July 29 $2,649 $1,349 [email protected] / +1-781-972-5402 Registration after July 29 $2,799 $1,399 Agenda BASIC PACKAGE (Includes access to 1 conference or Training Seminar. Excludes short courses.) Early Registration until June 10 $1,599 $849 Advance Registration until July 29 $1,799 $899 Registration after July 29 $1,949 $999 Barnett is a recognized leader in clinical Hotel & Travel education, training, and reference guides for life science professionals involved in Information Monday – Tuesday Tuesday (pm) – Wednesday Thursday – Friday the drug development process. For more Immunomodulatory Antibodies Combination Immunotherapy Adoptive T Cell Therapy information, visit BarnettInternational.com. Oncolytic Virus Immunotherapy Personalized Immunotherapy Biomarkers for Immuno-Oncology Registration Training Seminar: Immunology for Drug Preclinical & Translational Immuno-Oncology Clinical Trials for Cancer Immunotherapy ADDITIONAL REGISTRATION DETAILS Discovery Scientists Each registration includes all conference Information sessions, posters and exhibits, food functions, and access to the conference CONFERENCE DISCOUNTS proceedings link. Poster Submission: Poster abstracts are due by July 29, 2016. Once your registration has been fully processed, we will send an email containing a unique Handicapped Equal Access: In Click Here to accordance with the ADA, Cambridge link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact Healthtech Institute is pleased to arrange Register Online! [email protected]. * CHI reserves the right to publish your poster title and abstract in various marketing materials and products. special accommodations for attendees Alumni Discount: Cambridge Healthtech Institute (CHI) appreciates your past participation at the Immuno-Oncology Summit. As a result of the great with special needs. All requests for such Immuno-Oncology assistance must be submitted in writing Summit.com loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate. Please note: Our to CHI at least 30 days prior to the start records must indicate you were an attendee of the Immuno-Oncology Summit in the past in order to qualify. of the meeting. Group Discounts are Available! Special rates are available for multiple attendees from the same organization. To view our Substitutions/Cancellations Policy, go to healthtech.com/regdetails For more information on group discounts contact Cathy Almquist at 781-972-5547 or [email protected] Video and or audio recording of any kind is prohibited onsite at all CHI events. If you are unable to attend but would like to purchase the Event Proceedings CD for $750 (+shipping), please visit Immuno-OncologySummit.com.

250 First Avenue Needham, MA 02494 How to Register: Immuno-OncologySummit.com www.healthtech.com [email protected] • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288